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Abstract
Acute Lung injury (ALI) and the more severe acute respiratory distress syndrome
(ARDS) are respiratory maladies that present immense clinical challenges. ALI affects 200,000
individuals annually and features a 40% mortality rate. ALI can be initiated by both pathogenic
and sterile insults originating locally in the lungs or systemically. While immense research has
been poured into this disease in an effort to find a therapeutic strategy, the heterogeneously
diffuse nature of the disease has not yielded a cure for the disease. Death from this disease is
strongly attributed to reduced gas exchange from a severely compromised alveolar-capillary
barrier. The only way currently to manage this disease is through enhanced ventilation and
hyperoxic therapy.
Hyperoxic therapy is a common treatment given to over 800,000 patients each year to
treat respiratory maladies such as ALI. Prolonged exposure to oxygen at high concentrations
results in the development of a condition known as hyperoxic acute lung injury (HALI). In this
disease, the formation of reactive oxygen species damages healthy tissue and impairs gas
exchange. Hyperoxia is also a well-documented murine sterile lung injury model that replicates
the symptoms of ALI in lung injury patients. The ability of non-lethal dosages of hyperoxia to
resolve without lung fibrosis also enables the study of molecules associated with ALI resolution
and repair, a process not clearly understood
Inflammation in ALI is associated with disease progression, however pharmaceutical
interventions aimed at targeting the inflammatory cascade have failed in clinical trials for ALI.

ix

Recent reports point to an aberrant injury resolution mechanisms that may be more strongly
correlated with morbidity and mortality. There seems to be a homeostatic imbalance between
endogenous inflammation progression and resolution initiation. This is especially the case with
HALI, as significant ROS generation results in depletion of redox regulating antioxidants.
Resolution mechanisms associated with ALI in the oxygen toxicity setting is poorly understood.
Polyunsaturated fatty acids such eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are essential fatty acids that show immense antioxidant and anti-inflammatory action in
cases of acute injury. The lung mucosa is rich in DHA and following inflammatory insult DHA
is readily converted to resolution phase interaction products (resolvins), which have shown
immense proresolutionary potential in recent reports of acute injury. In the presence of aspirin,
more potent and longer-acting aspirin-triggered resolvins are formed. The effects of resolvins
and their aspirin triggered epimers have not been studied in an oxygen toxicity setting and are the
focus of this dissertation. For the first time, we show that one of these resolvin molecules, aspirin
triggered resolvin d1 (AT-RvD1), can enhance resolution of hyperoxic acute lung injury. In vitro
results reveals that AT-RvD1 treatment resulted in reduced interaction of two key players in the
HALI inflammatory cascade, the macrophage and alveolar epithelium. AT-RvD1 was able to
blunt macrophage cytokine secretion as well as inhibit epithelial cell cytokine secretion and
adhesion molecule expression. More importantly, AT-RvD1 blunted cytokine mediated
leukocyte-epithelial cell interaction in vitro. In a sublethal hyperoxic injury model, mice given
AT-RvD1 following hyperoxia exposure displayed reduced HALI pathological severity. ATRvD1 treatment resulted in reduced alveolar-capillary permeability, tissue inflammation,
proinflammatory mediator secretion, epithelial cell death, and leukocyte influx. Taken together
these novel results demonstrate the therapeutic potential of resolvins in the oxygen toxicity

x

setting. These results also arouse the idea that resolvins could be used to lessen the comorbidities
associated with oxygen therapy and improve recovery times of ALI patients.

xi

Chapter 1: Introduction
Lung Function and Structure
The lungs and respiratory system are one of the hardest working organ systems in our
body. While this organ plays an important role in blood vessel mechanics and serve as a shock
absorber for our heart, the ability of these cone shaped tissue masses to coordinate and promote
gas exchange for tissues is essential for survival. This is made possible due to the exposure of the
airway to the atmosphere and the large surface area provided by the lung to facilitate and
promote gas exchange [1]. Oxygen, inspired nasally or orally, is delivered to the vessels via the
lungs tree like structure. The trachea receives the oxygenated air and branches into the right and
left primary bronchi, which further branch off into smaller primary and tertiary bronchi and
bronchioles[2-4]. At the terminal end of these branches are the alveoli which are the site of
oxygen-carbon dioxide gas exchange. The lung contain over 700 million alveoli which account
for a massive surface area which facilitates the gas exchange (shown in Fig 1.1) [5]. Also of
benefit to this gas exchange is the close proximity of adjacent capillaries which line and wrap
around the alveoli. The alveolar epithelial cells adjacent to these capillaries provide a very thin
layer upon which gas can readily diffuse [5]. Resident alveolar macrophages serve as innate
immune defense to detoxify the lungs of foreign matter and cell debris, as well as initiate the
inflammatory cascade following lung injury [6].
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Alveolar Epithelium
The alveolus is the primary site for gas exchange [1,7]. Millions of alveoli contribute to
702 meters of surface area to facilitate carbon dioxide-oxygen exchange [8]. The alveoli also act
as a physiological barrier and immunological responder to environmental and pathogenic insults.
The alveolar epithelium is comprised of two types of pneumocytes, type 1 and type 2 alveolar
epithelial cells (AECs). Squamous type 1 AECs cover over 80% of alveolar epithelium but only
represent 20% of alveolar epithelial cells [9]. The cells provide a thin cellular layer enabling gas
exchange from adjacent capillaries. The squamous morphology of these cells also creates a large
alveolar surface area which is required due to the relative internal insolubility of oxygen. More
recently it has been found that these cells aid in fluid transport [10,11]. While these cells play an
important role in gas exchange, they are very fragile and high amount of cell death from
pulmonary insults results in a compromised alveolar barrier and pulmonary edema[10]. Type 2
AECs have a cuboidal morphology and are mainly responsible for the production surface active
lipoproteins known as surfactants. These surfactants decrease the alveolar surface tension and
prevent alveolar collapse, a precursor to partial or total lung collapse (atelectasis). Surfactant also
s helps to facilitate the diffusion of oxygen across the alveolar epithelium [12,13]. Type 2
pneumocytes are more numerous than 1 AECs, representing approximately 80% of cell
population but only 20% of the surface area. Type 2 AECs are more resistant to noxious stimuli.
Following injury, type 2 AECs serve as progenitor cells and terminally differentiate into type 1
AECs in order to facilitate re-epithelialization of the alveolar barrier [10]. These cells also assist
in fluid transport to reduce pulmonary edema. These cells are in detail in figure 1.1.
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Alveolar Macrophage
Representing over 90% of the alveolar resting immune cell population, the macrophages
are the sentinel cells in healthy alveoli. Alveolar macrophages sense pathogenic stimuli and
respond by the production of proinflammatory cytokines in order to recruit first responder cells
such as polymorphonuclear leukocytes (neutrophils) to the site of injury. These cells play a role
of tissue homeostasis through phagocytosis of apoptotic and necrotic cells [6]. Because of their
enhanced activity, alveolar macrophages are adaptable and secrete a variety of factors depending
on the stimulus encountered [14]. In the resolution stage of injury, these macrophages secrete
pro-resolution factors that stimulate alveolar re-epithelialization and reduced leukocyte
infiltration[15]. Noxious stimuli caused by trauma, sepsis, aspiration, or oxidative stress can
result in activation of an immense inflammatory cascade propagated by alveolar macrophages
that leads to the development of a disease known as acute lung injury [6]. These cells are in
detail in figure 1.1

Acute Lung Injury Historical Perspective, Epidemiology, and Risk Factors
ALI is respiratory syndrome that can be characterized by tissue pulmonary edema, altered
gas exchange, alveolar-capillary membrane dysfunction, and a deregulated and excessive
inflammatory profile [16-18]. The heterogeneously diffuse nature of this disease makes
management by Intensive care unit (ICU) physicians a very challenging problem. This
progressive respiratory disease represents a progressive spectrum of inflammation and alveolar
damage, where early onset of the disease is classified as ALI and the more severe form of ALI is
termed acute respiratory distress syndrome (ARDS)[19].
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Historical Perspective
Ashbaugh and colleagues described an adult respiratory distress syndrome in 1967
utilizing a subset of patients under mechanical ventilation as a result of trauma, viral infection,
and pancreatitis [20,21]. This disease displayed acute onset, with symptoms present within two
hours of the initial inflammatory stimuli. In this study, 12 patients were found displayed
symptoms of acute onset tachypnea, systemic hypoxemia, chest x-rays showing panlobular
infiltration, and atelectasis. These patients did not respond to conventional respiratory therapies
and the disease symptoms were very similar to those seen in neonatal respiratory distress
syndromes. The term adult respiratory distress system was coined as a result of this investigation.
Over the years adult respiratory distress syndrome has been changed to acute respiratory distress
syndrome and the clinical criteria for diagnosis of ALI/ARDS has evolved to include early onset
respiratory distress, diffuse pulmonary infiltrates as measured by chest x-ray, non-cardiogenic
hypoxemia, and a severity scale of blood oxygenation in order to determine if the patient has
mild or severe ARDS [22].
Following the initial description of ARDS by Ashbaugh et al., Murray and colleagues
proposed a lung injury score (LIS) composed of four parameters scored on a scale of 1 to 4 in
order to decipher ALI/ARDS severity [23]. Once the parameters are scored the LIS is calculated
by adding the score from each parameter and dividing by the total number of parameters used
with a score of 0 indicating no injury, 0.1-2.5 indicating ALI, and a score greater than 2.5 giving
an indication of severe ARDS. The LIS is still a standard that is commonly used today and takes
into account chest CT or x-ray examination, hypoxemia and oxygen saturation score, lung
biomechanics, and positive end expiratory pressure (PEEP, ) which is defined as alveolar
pressure above atmospheric pressure following expiration. This helped to deciphering mild cases
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of ARDS that are able to be resolved from more severe forms that may lead to more chronic lung
disease such as pulmonary fibrosis.
To further develop a uniform definition and to coordinate and properly enroll patients
into clinical studies to assess therapeutic strategies for ARDS, the North American-European
Consensus Conference (NAECC) was convened in 1994 [24,25]. At this conference, the term
acute lung injury as a mild form of ARDS was coined. The recommendation from the panel was
that a ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2), a
hypoxemia indicator, be used to differentiate between ALI and ARDS. A PaO2/FiO2 less than
300 would suggest ALI and less than 200 would suggest ARDS. The NAECC definition did not
incorporate PEEP into their proposed definition of ALI or ARDS in order to maintain simplicity
and uniformity. In order to exclude patients with pulmonary edema as a result of cardiogenic
disorder, the NAECC definition added the stipulation that the pulmonary artery wedge pressure
(helps to detect left ventricular failure) had to be less than 18mmHg, with no indication of
pulmonary hypertension. Diffuse bilateral pulmonary infiltrates, indicative of pulmonary edema,
was the final criteria used to identify ALI/ARDS in the NAECC definition, however a
description between ALI and ARDS via chest radiograph was not provided. The major drawback
to this definition was the failure of an empirical classification of the term acute, which was also a
drawback of previous ALI/ARDS definitions, however the uniform diagnostic criteria that used
in NAECC definition has made it easier to classify ALI and ARDS patients for enrollment into
clinical trials. The more recent Berlin definition (2013) has gone one step further in stratifying
ARDS into mild moderate and severe via PaO2/FiO2, and has shown better prognostic value in
helping to determine proper length of ventilation and mortality risk for ALI/ARDS patients [26].

5

Epidemiology and Risk Factors
ALI, a syndrome of respiratory failure, is a major clinical problem in the United States.
With a high incidence rate, affecting nearly 200,000 annually and a significant morbidity and
mortality rate, ALI represents a significant source of health care expenditure with a cost of 3.5–6
billion dollars annually [27-30]. Annually 75,000 deaths are associated with acute lung injury
each year, resulting in a 35-40% mortality rate [29]. African Americans demonstrate
significantly higher ALI mortality rate than Caucasians [31]. The mean age for acute lung injury
patients is 60 years of age across populations and demographics. Age of patients is a strong
predictor of disease outcome. Variation among ALI incidence and mortality rate does exist and
thought to be due to ALI diagnostic reliability and availability of resources in the ICU. The
annual incidence of 200,000 is dependent on clinical care reporting from the ICU, which would
suggest that ALI/ARDS occur much more often in the clinical setting than what is traditionally
reported [32-34].
As mentioned previously, ALI is a disease of heterogeneous origin and can result from
sterile or pathogenic injury. While sepsis reports as the most common cause of this syndrome
with 35-45% of sepsis patients in ICU settings developing ARDS, sterile insults such as severe
trauma, circulatory shock, pneumonia, and acid aspiration also represent the most common
clinical insults that lead to acute lung injury development [33,35-38]. ALI can result from
primary insults local to the lung, or secondary insults that result from systemic injury (Table 1.1)
Primary insults that lead to acute lung injury include pneumonia, acid aspiration, chest trauma,
pulmonary thrombus and embolism, reperfusion injury, mechanical stretch related injury and
near drowning. Second insults that lead to acute lung include but are not limited to sepsis,
circulatory shock, burns, drug overdose, acute pancreatitis, multi-organ failure and multiple
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blood transfusion. A history of chronic alcohol abuse, chronic lung disease such as chronic
obstructive pulmonary disease (COPD) and While it has been difficult to assess the molecular
determinants of injury, many reports have highlighted an ungoverned inflammatory response as
key to the progression of ALI and ARDS [32,39].

Acute Lung Injury Pathology
Irrespective of whether the onset of ALI occurs via primary or secondary insults, ALI
patients display a similar disease pathology. A critical underlying mechanism associated with
ALI is the breakdown of the alveolar-capillary membrane [22,23,29,40]. Initial insults such as
stress and inhalation of noxious chemicals can lead to death of fragile alveolar type 1 and injury
to alveolar type 2 cells. This leads to a breakdown of the alveolar barrier and allows the alveolar
space to be flood with edema fluid. Proteins contained in this fluid destabilize the pulmonary and
increase alveolar surface tension. Because of this process gas exchange is severely compromised
and hypoxemia develops. Apoptotic epithelium is an early event in ALI that also is a key
initiator of the acute onset of inflammation that is tied to ALI progression [10,41]. Diseased
alveoli in ALI is shown in figure 1.1.
Activation of normally quiescent alveolar macrophages is a hallmark of alveolar
inflammation. Alveolar macrophages sense the cell debris from apoptotic and necrotic AECs as
well as the destabilized pulmonary surfactant and start to polarize to a more proinflammatory
phenotype. Alveolar macrophages serve as the central effector cells to initiate the early
inflammatory phase which can occur in as little as 6 hours following injury [5,15,42]. These
macrophages communicate with adjacent cells through the secretion of proinflammatory
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cytokines and chemokines such as interleukin-1beta (IL-1β) and tumor necrosis factor-alpha
(TNF-α). Although TNF-α levels do not predict ALI patient outcome, IL-1β has been shown to
be the most bioactive cytokine in acute lung injury patients [43,44]. IL-1β concentration
positively correlates with ALI pathological progression and patient outcomes. The secretion of
IL-1β in relation to its antagonist IL-1 receptor antagonist (IL-1RA) is 1:1 ratio, however in
ALI/ARDS patients this ratio can balloon to 10:1 IL-1β. Once secreted, IL-1β can act in an
autocrine manner to serve as a positive feedback mechanism to enhance cytokine product.
Paracrine activity on adjacent AECs results in the production of proinflammatory adhesion
molecules and cytokines such as interleukin-6 and interleukin-8 through a mitogen activated
protein kinase (MAPK) or nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) dependent mechanism. These cytokines create a cytokine storm or gradient by which attract
circulating leukocytes such as monocytes and neutrophils to the site of injury [16,45]. This is
shown in detail in figure 1.2.
ALI features an immense leukocyte influx into the injured area. Leukocytes such as
neutrophils migrate into the site of tissue injury utilizing adhesion molecules expressed on the
alveolar endothelial and epithelial surface. The concentration of neutrophils in the
bronchoalveolar space positively correlates with severity of ARDS and disease progression
[9,22]. Neutrophils represent the first responders to the site of injury and release a wide array of
antimicrobial molecules such as proteinases, cationic peptides, and oxidants. While in pathogenic
conditions, these antimicrobial molecules are extremely helpful, in cases of sterile injury such as
oxidant stress related lung injury, the release of these chemicals by neutrophils prove to be
cytotoxic to healthy alveolar tissue and further activate immune cells [46-51]. Neutrophils that
have polarized to an inflammatory phenotype and migrate into the tissue area have an average
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life span of 6 to 8hrs and quickly undergo apoptosis. Neutrophil debris further activates alveolar
macrophages and enhances the immune response, creating a vicious cycle that does not subside
in most cases without medical intervention [15]. In patients that recover from acute lung injury,
curtailing the ungoverned immune response is key to recovery. If left untreated and unattended
to, loss of surfactant, alveolar flooding, reduced gas exchange, and aberrant repair mechanism
lead to proliferation of fibroblasts and the development of fibrosing alveolitis which can be
histologically apparent as soon as five days following the initial injury [52].
While the pathology of ALI has been well studied, the diffuse nature of insults that lead
to ALI make it difficult to dissect the molecular mechanisms associated with disease. Further
complicating the matter is the heterogeneous nature of the injury, as ALI patients do not display
uniform injury throughout the lung and can demonstrate healthy and diseased tissue in the same
lobe [53,54]. Cytokines play a major role in propagation of the inflammatory signal that drives
this disease. Systemic and local cytokine production by epithelial cells and macrophages
respectively play a key role in leukocyte influx that is also a hallmark of ALI/ARDS. Lung repair
mechanisms are associated with decrease proinflammatory cytokine production as well as
increase in proresolutionary mediators. Clearance of these cytokines is associated with injury
resolution [55,56]. The role of endogenous mediators that contribute to this inflammatory
regulation is not clearly understood.
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ALI Treatment Strategies
Pharmaceutical Treatment Interventions for ALI
While ALI and ARDS are mediated by inflammation, pharmacological treatments aimed
at improving respiratory and decreasing inflammation have all failed in clinical trials. Clinical
trials aimed at delivering glucocorticoids in the late and acute phases, the antioxidant nacetylcysteine, and inhaled nitric oxide have all failed to deliver a benefit as reported by the
National Institute of Health’s ARDS network [57].
Beta-2 adrenergic agonists (β-2 agonists) have served as a useful therapeutic for
pulmonary injuries such as asthma and COPD [58,59]. Preclinical data of β-2 agonists for
treatment of ALI revealed that β-2 agonists reduce pulmonary edema through enhanced fluid
transport and attenuate inflammation. Although preclinical data was promising, ARDS network
sponsored clinical trials were stopped due to futility, citing an inability to optimally deliver the
albuterol to the pulmonary epithelium [57]. COPD and asthma are also diseases of pulmonary
bronchiolar epithelium which contain significantly more smooth muscle than do alveoli which
contain only a relatively small amount of smooth muscle. Since β-2 agonists act on smooth
muscle, this may be a reason why treatment was not effective ALI/ARDS patients. Beneficial
treatment strategies for ALI mostly result in a form of supportive care, and no effective treatment
exists for ALI/ARDS patients. Steroids such as glucocorticoids have not only failed to provide a
benefit to ALI patients, but have also lead to increase complications and increased risk of
infection.
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Mechanical Ventilation as Means of Supportive Care
Mechanical ventilation is a critical clinical intervention used to improve oxygenation and
reduce hypoxemia in ALI/ARDS patients [10,60]. Mechanical ventilation delivered through the
tracheal tube combined with PEEP and prone positioning have shown enhanced oxygenation in
ALI/ARDS patients. Tidal volume accounts for the amount of air that is either inhaled or exhaled
in a single breath. A large multicenter randomized drug trial sponsored by the ARDS network
revealed that low tidal volume ventilation conferred significant advantage over patients who
received high tidal volume ventilation. These patients had reduced ventilator days as well
displayed decrease organ failure. The inflammatory response associated with ALI and ARDS
was also decreased, which can be associated with the decrease in barotrauma associated with
mechanical stretch of the alveolar epithelium [61]. Along with low tidal volume ventilation,
Fluid management and enteral feeding over parenteral feeding of omega-3 fatty acids has shown
improvements in patient outcomes. The ARDS networks reports demonstrated that fluid
management improves oxygenation in ALI/ARDS patients while also decreasing disease
severity. Patients that receive enteral feeding within 48 hours of mechanical ventilation have
reduced mortality and morbidity and a lower rate of infection than patients who are fed
parenterally [62].
Other forms of supportive care are used to enhance the efficiency of ventilation for
ALI/ARDS patients. Recent research has found that prone positioning when sleeping can
enhance oxygen saturation by 50% to 70% during ventilation. Prone positioning can ventilation
perfusion matching increases lung compliance and decreases fluid buildup in the alveolar space
[63-66]. Ventilation is also delivered in a tracheal tube with PEEP. Following alveolar injury, an
intrapulmonary shunt forms which basically when perfused alveoli fail to deliver oxygen to the
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adjacent blood supply. PEEP reduced intrapulmonary shunt through proper matching of
ventilation and perfusion. Alveolar congestion and obstruction is also a common hallmark seen
in injured alveoli, how PEEP enhances alveolar patency and improves alveolar function
[19,67,68]. Although supportive care such as mechanical ventilation decreases morbidity and
reduces hypoxemia, outcomes of survival are unaffected. This creates a need for more effective
treatment strategies aimed at improving ALI/ARDS patient outcome.

Oxygen Therapy and Hyperoxic Acute Lung Injury
Oxygen Therapy Application
Oxygen therapy remains the chief form of supportive care for patients who suffer from
diseases that result in decreased lung function such as ALI. Each year there are over 800,000
cases that require oxygen therapy, resulting in a healthcare expenditure of 1.8-2 billion dollars
[69]. The delivery of oxygen to healthy tissues is especially important in chronic lung injury
cases such as asthma and COPD. As noted previously, patients who suffer from respiratory
maladies such as the inhalation of noxious stimuli exhibit poor gas exchange due to lung injury.
This poor gas exchange leads to arterial hypoxia and subsequent systemic hypoxemia which can
result in tissue oxygen debt, reduced cell metabolism and physiological functioning which can all
lead ultimately to organ failure [19,70]. Oxygen supplementation attenuates systemic hypoxemia
through increased delivery of oxygen from blood to tissue, circumventing the poor gas exchange
issue faced by lung injury patients. Normally, blood oxygen is attached to hemoglobin, with
some oxygen being dissolved in blood plasma. When oxygen therapy is administered, the excess
oxygen saturates the hemoglobin and slightly increases arterial oxygen concentration, the
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enhanced arterial oxygen results in increased oxygen tension between the capillaries and oxygen
metabolizing cells [71]. Since the main mechanism of tissue oxygenation relies on diffusion, the
enhanced oxygen tension results in greater diffusion and transfer of oxygen from capillaries to
tissue cells.
Normal inhalation results in the intake of 21% oxygen from the atmosphere. During times
of increased oxygen debt, patients can receive oxygen therapy in the form of 24-100% through
tightly fitting positive pressure flow masks. Patients at the higher end of the spectrum however,
still face a challenge of decreased oxygen delivery to tissue, even with delivery of higher
percentage of oxygen (90-100%). This is due to hemoglobin saturation and enhanced dissolved
oxygen in blood plasma. The loss of oxygen in the blood to plasma dissolution, results in the
delivery of only 1/3 of required oxygen for resting tissue cells [72]. This can be alleviated
through hyperbaric oxygen therapy. Hyperbaric oxygen therapy delivers high doses of oxygen at
a pressure greater than one atmosphere to patients with severe oxygen debt. Exposure to oxygen
at a pressure three times normal atmospheric pressure results in decreased oxygen dissolution in
blood plasma and an increase in oxygen delivery to resting cells independent of hemoglobin
involvement. While oxygen therapy is a necessary form of supportive care that cannot be
bypassed due to need of oxygen from healthy tissue, there is a narrow margin between effective
and toxic dosages. A margin that is still clearly not understood [22,73,74]. Furthermore,
enhanced oxygen delivery can result in excess tissue oxygenation and thus oxygen toxicity. No
organ is more susceptible to this oxygen toxicity than the lungs, where hyperoxia can cause the
occurrence of a disease known as hyperoxic acute lung injury [19,75] hyperoxic.
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Hyperoxic Acute Lung Injury
Oxygen toxicity is a result of excess oxygen exposure to tissues and organs. In the
alveoli, oxygen toxicity results when the partial pressure of oxygen exceeds that of oxygen in the
atmosphere. Prolonged breathing of oxygen at a fraction of inspired oxygen greater than .6 can
lead to serious medical complication and the incidence or exacerbation of an acute lung injury
termed hyperoxic acute lung injury (HALI) [76].
The first report of HALI in human was from in 1958. In their report, Prat and colleagues
discovered increase in alveolar capillary size following hyperoxic overexposure to patients
suffering from respiratory complications [77]. Various reports would follow to try to further
classify hallmarks of HALI with such features as a hyaline membrane, but confounding details,
such as pre-existent acute lung injury and low alveolar fraction of inspired oxygen, would
decrease the enthusiasm of such claims [78-84]. Two of these cases (Friedmen et al and Nash et
al) however would like oxygen therapy and ventilation to respiratory complications in neonates
and death in adults. This caused increase attention to be paid to hyperoxia in the clinical setting.
Since then case reports investigating HALI have focused on mechanical ventilation utilizing
PEEP to control the fraction of inspired oxygen administered. However, for patients with severe
hypoxemia, high dose oxygen and prolonged exposure is unavoidable. Studies of patients
exposed to hyperoxic treatment display tracheobronchitis, reduced lung permeability,
deteriorated lung biomechanics (resistance and compliance), and poor oxygen saturation [85-87].
Sustainable measures to improve oxygen therapy efficiency and decrease the harmful effects of
hyperoxia have not been properly elucidated.
As with other forms of ALI, HALI is mediated by an acute inflammatory process and if
left untreated can progress to ARDS. Failure to reduce the increased fraction of inspired oxygen
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in HALI Is usually fatal. This is due to the uncontrolled production of a significant amount of
reactive oxygen species (ROS) [19]. ROS are normally produced in cells as a byproduct of
respiratory burst. Natural antioxidants such as glutathione, reduce ROS and thus limit their
harmful effects on tissue. In hyperoxic lung injury however the immense amount of reactive
oxygen species overwhelms and depletes natural antioxidant stores leading to an oxidantreduction (Redox) imbalance. This redox imbalance results in the breakdown of the alveolarcapillary membrane and inability of lung mucosal clearance [88]. Lipid peroxidation results in
alveolar epithelium as well as DNA oxidation and damage. These signals initiate powerful
proinflammatory signals and apoptotic cascades in AEC type 2 and type 1 cells respectively
[75,76,88]. Debris from alveolar epithelial cells and well inactivated pulmonary surfactant
activate alveolar macrophages who secrete proinflammatory cytokines such IL-1β into the
alveolar environment [89-92]. Recruitment of neutrophils though cytokine and adhesion
molecule mediated signaling results in another harmful round of ROS being secreted from
neutrophil granules. If left untreated or unresolved, there is a fibroproliferative phase that
develops where enhanced pulmonary interstitial fibroblast activation results in hyaline membrane
formation and collagen deposition [52,93]. It has been shown previously that this the critical
point of no return between tissue resolution and chronic injury progression to pulmonary fibrosis
[55,94-98]. While the molecular determinant involved in the progression of the disease have
been identified, the molecules involved in HALI resolution have not been thoroughly
investigated.
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Hyperoxia in Animal Models of Lung Injury
Since its discovery in 18th century, oxygen has instantly been thought of as a therapy for
patients with respiratory complications. In the same breath, research have been skeptical about
its potentially toxic effects. Shortly after its discovery, Lavoisier found that guinea pigs exposed
to a high fraction of inspired oxygen died of what he termed “violent inflammation” [99].
Postmortem examination of the lungs revealed red discoloration, lung stiffening, and severe
hemorrhage and clotting. This findings of Lavoisier was confirmed when Watt and colleagues in
a study of kittens reported extensive inflammation following hyperoxia exposure [100]. In
another examination of extensive hyperoxia exposure in 1866, Dumas and colleagues discovered
that post mortem lungs of dogs were considerably stiff, had severe blood clotting and
coagulation, as well as displayed reduced mucus clearance [100]. Since these initial studies in
the first 100 years following oxygen discovery, over 50 more studies spanning over 9 species
have highlighted the debilitating effects of hyperoxia exposure at a fraction of inspired oxygen ≥
.8 atmospheres. In general these animals survived lethal oxygen exposure between 3 and 6 days.
The only animals that have shown particular resistance to oxygen exposure are reptiles and
amphibians in a normal temperature setting [19]. This suggests that hyperoxia exposure may be a
reproducible model for ALI.
Animal models that mimic acute lung injury are essential to demystifying the mechanism
associated with injury progression and repair. Matute-Bello and collegues describe a good ALI
model as one that reproduces the classical hallmarks of the disease in both the inflammatory and
repair phase [101]. Examples of animal models along with their advantages and disadvantages is
seen in detail in tables 1.2 and 1.3. Ideally, animal models should reproduce the alveolarcapillary barrier dysfunction, tissue inflammation and leukocyte influx, and enhanced alveolar

16

permeability. Under continuous exposure to disease causing agents, animals should exhibit
enhanced collagen deposition, decreased lung mechanics and hyaline membrane formation as
part of the fibroproliferative phase. However if exposure to disease causing agents such as
hyperoxia are removed during the initial acute phase (first three days) then the lung injury should
resolve in most cases [94,102-105]. A look into indexed articles that investigate lung injury
reveals that 12% utilize the hyperoxia rodent model to study ALI pathology. This model will also
be used in the in vivo experiments of this dissertation due to its reproducibility and ability to
mimic clinical ALI hallmarks [19,75,101,106]. Our previous reports, as well those of other
laboratories, have demonstrated that hyperoxic (95% Oxygen) exposure for 24-72hrs results in
significant damage to the alveolar epithelium, enhanced proinflammatory transcription factor
activation, proinflammatory cytokine signaling, and neutrophil influx [89-92,107-111].
Exposure to normal room air (normoxic conditions, 21% oxygen) results in proliferation of type
2 AECs and healing of the lung tissue with no fibrosis present. Therefore this model is a reliable
animal model to study lung injury resolution from hyperoxic acute lung injury [101]. Since
oxygen is a necessary form of supplementary care for ALI patients, the use of the hyperoxia
model may generate novel therapeutics that can alleviate hyperoxic lung injury and thus increase
the efficacy of oxygen therapy, and enhance the resolution of ALI/ARDS.

Lung Injury Resolution
Acute inflammation is an important response to tissue injury and infection. This well
regulated process, if left ungoverned can severely compromise lung function and further
exacerbate the injury. This paradigm of an over active inflammatory process is seen in sterile
injuries of the lung such as hyperoxic insult, where the innate immune system contributes to the
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death of healthy tissue through the release of cytotoxic antimicrobial agents [19,106]. If left
unresolved tissue inflammation can lead to irreparable fibrotic development, where clinical
interventions are less successful and lung transplant is essential down the line in order to
decrease morbidity and mortality [52]. In most instances removal the molecular mechanism that
govern lung injury resolution can finally overpower the inflammatory signals and restore tissue
homeostasis following clearance of noxious stimuli [94].
Although the resolution of injury was known at the tissue level for many years, it was
thought to occur by means of a passive process where the hallmarks of injury would decrease
overtime. The flow of chemical mediators such as cytokines and chemokines would decrease
over their half-life and burn out. Following the clearance of bacteria or removal of noxious
stimuli, neutrophils would be cleared via phagocytosis or efflux via lymphatic systems to the
spleen. Enhanced division and subsequent differentiation of AEC type 2 cells into AEC type 1
cells would repopulate the epithelial barrier and promote edema clearance and boost surfactant
production (This is shown in detail in fig. 1.3). Recently however the discovery of several
soluble lipid mediators that seem to play a role in the biochemical process of acute injury
resolution have caused a paradigm shift in the understanding of injury resolution, providing key
evidence that hallmarks of resolution such as decreased neutrophil influx are indeed the result of
an active biochemical process [98,112,113]. These pro-resolution mediators are active in the
resolving phase of injury which can be defined in terms of maximal inflammatory time point
(neutrophil influx) to the point where inflammation no longer persists (complete clearance of
neutrophils) [15,55,96,98,112,114,115]. It is also important to distinguish them as proresolution
mediators rather than anti-inflammatory mediators.
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The current depletion therapy paradigm of anti-inflammation results in the attenuation of
key signals in inflammation. These signals however are also important in the initiation of injury
resolution patterns. Cyclooxengases and lipoxygenases play important roles in inflammatory
initiation through the production of prostaglandins and proinflammatory omega fatty acids
[98,112]. These molecules however also play an important role in the production of key preresolutionary molecules known as resolvins, which will be discussed in detail later in this
chapter. Cyclooxegase and lipoxygenase inhibitors would partially block the inflammatory
cascade, but through their inhibition of the molecule would also blunt resolution and contribute
to persistent inflammation, a well-documented problem in ALI/ARDS. This is also true for
cytokine therapy of early pro-inflammatory cytokines such as IL-1β and TNF-α, which also play
a role in injury repair [116]. Thus, endogenous pro-resolution mediators, such as resolvins, that
decrease the inflammatory response and enhance the active resolution of cellular injury and
tissue catabasis represent a new and intriguing avenue for therapeutic interventions of a variety
of maladies associated with unresolved inflammation such as HALI.

Resolution Phase Interaction Productions
Experimental models that are self-limiting in nature and resolve on their own have been
used to discover and characterize molecules that are important aspects of the body’s natural
proresolution machinery [15,55,94,96,117,118]. Essential polyunsaturated fatty acids (PUFAs)
such as omega-3s have been noted for their intense anti-inflammatory and antioxidant
potential[119]. Analysis of essential omega-3 fatty acid eicosapentaenoic acid (EPA, 5Z,8Z,11Z,
14Z,17Z-eicosapentaenoic acid) and docosahexaenoic acid (DHA, 4Z,7Z,10Z,13Z,16Z,19Zdocosahexaenoic acid) reveals a 0.5%-2.8 and 1.3% percent to 5% composition of total fatty
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acids respectively. Analysis of cystic fibrosis patients reveals a rich fatty acid content of DHA in
the lungs of healthy patients. This is an important polyunsaturated fatty acids such as EPA and
DHA display strong anti-inflammatory properties [98,120]. PUFA’S such as DHA and EPA are
also readily broken down into pro-resolutionary compounds known as resolution phase
interaction products (Resolvins).
Resolvins are metabolic byproducts of the essential omega-3 fatty acids EPA and DHA.
Resolvins derived EPA are termed E-series resolvins and resolvins derived from DHA are
termed D-series resolvins. Resolvins were first identified by LC-MS/MS analysis of murine
inflammatory exudates in the resolution phase of injury by Serhan and colleagues
[112,113]. In this study, it was found cytokine challenge resulted in a rapid generation
inflammatory leukotriene and prostaglandins in the acute inflammatory phase. Class switching of
these proinfammatory leukotrienes was associated with decreased neutrophil influx following
cytokine challenge coupled with aspirin treatment. These experiments generated new
compounds that showcased an EPA and DHA backbone and contributed potent pro-resolutionary
effects at nanomolar and picomolar dosages. Acetylation of the cyclooxygenase enzyme by
aspirin serves to enhance the effect of both e-series and d-series resolvins [116,120]. This is
because canonical resolvins that are not aspirin triggered exhibit a very short half-life and are
quickly enzymatically processed. While these enzymatically altered variants do still possess
some anti-inflammatory and pro-resolutionary ability, there are far less efficient than
unprocessed precursors. Aspirin triggered-resolvins of the D series show potent antiinflammatory levels in reports of sterile injury, however the effect of aspirin triggered d series
resolvins have not been investigated in an oxygen toxicity setting.
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Synthesis of D-Series Resolvins
D-series resolvins, most notably resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,
19Z-docosahexaenoic acid) and resolvin D2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Zdocosahexaenoic acid), are derived from DHA and their synthesis has been previously described
by Serhan and colleagues [121]. DHA is an essential fatty acid obtained from diet and is present
in large quantities in the brain, eye, and lung. Following inflammatory injury DHA is converted
to d-series resolvins in a transcellular pathway involving epithelium or endothelium in the first
step and leukocytes in the second step. While mechanisms of regulation of resolvin biosynthesis
are not fully understood, the appearance of these molecules are correlated with the resolutionary
phase of acute injury [98].
Canonical d-series resolvins such as resolvin-d1 are converted from DHA in a
lipoxygenase dependent mechanism (shown in figure 1.4). Following inflammatory injury
lipoxygenase-15 in the endothelium or epithelium acts on released DHA to form 17S-hydroxyDHA (17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid) This 17S-hydroxy-DHA is further
activated on by neutrophil derived lipoxygenase-5 to produce resolvin-d1. Resolvin D1 has
shown potent antiinflammtory properties in murine inflammatory acute injury however concerns
about half-life and rapid inactivation persist [94,98,115,119]. In the presence of aspirin a
molecule known as aspirin triggered-resolvin d1 is produced and displays significant resistance
to enzymatic inactivation and is more potent than resolvin d1.
Aspirin triggered-resolvin d1 is triggered through a similar transcellular pathway this
time involving the use of cyclooxygenase-2 (COX-2) in the first step of the reaction [112,122].
Normally COX-2 is involved in the production of pro-inflammatory omega-6 fatty acids.
However, in the presence of aspirin, COX-2 is acetylated and there is an alteration in the
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hydrophobic binding pocket of the molecule that alters substrate preference to the production of
omega-3 fatty acids. DHA is processed by COX-2 to form 17R-hydroxy-DHA (17R-hydroxy4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) which is then converted to aspirin-triggered
resolvin d1 (7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoic acid) [98].
Biosynthesis of AT-RvD1 is shown in figure 1.4. The intermediates of both resolvin d1 and
aspirin triggered-resolvin d1 both have anti-inflammatory biological function.

Summary and Objectives
Acute lung injury is a debilitating clinical disease that is hallmarked by overactive
inflammation and an aggressive inflammatory profile. Noxious stimuli results in the polarization
of macrophages and the alveolar epithelium to a proinflammtory phenotype characterized by the
secretion of cytokines such as IL-1β, which has been linked to disease progression and
pulmonary fibrosis. Investigation into acute lung injury has not resulted in a cure for the disease
and are maintained via supportive care mechanisms of ventilation and oxygen therapy. While
oxygen therapy may be a necessary form of supportive care for patients with high oxygen debt,
the prevalence of oxygen toxicity and reactive oxygen formation can further exacerbate already
debilitated patients. Hyperoxia in animal models has also proven to be a reliable way to
investigate lung injury toxicity and resolution, the latter of which is not clearly understood. Since
pharmacological interventions have not fared clinically with lung injury patients and abberant
repair mechanism is associated with this disease, investigating endogenous resolution
mechanisms as an adjuvant to oxygen therapy would be of considerable therapeutic promise.
Resolvins have displayed considerable therapeutic promise is a wide array of acute injuries. The
investigation of these molecules in an oxygen toxicity setting is lacking. In
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this dissertation we plan to investigate the therapeutic promise of D-series resolvins, which are
reported to have considerable therapeutic benefits at pico- and nanomolar ranges. The resolvins
will be investigated in vitro for their ability to curb inflammatory functions of macrophages and
alveolar epithelial cells in vitro. Further, we will examine the therapeutic potential of aspirintriggered resolvin d1 in vitro for its ability to decrease HALI severity and enhance lung
resolution.
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Tables & Figures

Figure 1.1: Healthy vs Diseases Alveolus in Acute Lung Injury. The normal alveolar
epithelium is composed of the alveolar type 1 and type 2 cells. Alveolar type 1 cells provide a
thin cellular layer with immense surface area in which to facilitate gas exchange between the
adjacent capillary epithelium. The alveolar type 2 cells maintains alveolar architecture through
the secretion of tension diminishing pulmonary surfactant. The alveolar macrophage is
responsible for clearing our alveolar debris as well as sensing of pathogens and noxious stimuli.
Following inflammatory insult, there is a breakdown in the alveolar capillary barrier due to cell
death and flooding of the alveolar space. Alveolar edema deactivates pulmonary surfactant and
activated macrophages secrete proinflammatory cytokines which activate alveolar type 2 cells
and help to recruit circulating leukocytes. Cytotoxic molecules secreted by recruited cells such
as neutrophils contribute to a dangerous inflammatory phase that if left untreated can be fatal.
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Table 1.1: Causes of Acute Lung Injury. Acute lung injury is a disease of heterogeneously
diffuse origin and can be caused by primary (local to respiratory system) or secondary (systemic)
insults. A list of these insults is provided in this table.
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Table 1.2: Examples of Direct Lung Injuries Models. Direct lung injury is one that originates locally in the in the pulmonary space.
Models that mimic the pathology of local injury are listed in this table

26

Table 1.3: Examples of Indirect Lung Injuries that Lead to ALI: Indirect lung injury is one that originates away from the lung and
leads to systemic inflammation.. Models that mimic the pathology of systemic lung injury are listed in this table.
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Figure 1.2: IL-1β mediated activation of the pulmonary epithelial inflammatory response. IL-1β is the most bioactive cytokine in
lung injury patients. Its secretion in ALI is directly correlated to disease outcome and progression to pulmonary fibrosis. IL-1β
receptor activation is involved in the activation of proinflammatory epithelial cell functions such as cytokine secretion, adhesion
molecule expression, and leukocyte trafficking. This thought to work through a MAP kinase and NF-κB mediated pathway.
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Figure 1.3: Inflammation vs Resolution Time points. A. Insults in acute injury lead to the activation of resident immune cells and
the secretion of cytokines and chemokines. Once this inflammatory process is initiated it proceeds with the recruitment of leukocytes,
which can further deteriorate the alveoli with the release of toxic molecules such as ROS. Failure to fix this will result in chronic
injury. Resolution however involves the use of specialized lipid mediators known as resolvins to decrease leukocyte influx, enhance
clearance of dead cells and reestablishment of the fragmented alveolar-capillary barrier. B. A temporal representation of inflammation
vs resolution is depicted above.
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Figure 1.4: Biosynthesis of D-series Resolvins. Docasahexaenoic acid (DHA) is an essential part of our diet. DHA also serves as
an endogenous anti-inflammatory molecule. Following injury, DHA is cleaved in a transcellular pathway as shown above to produce
pro-resolution molecule resolvin-d1. In the presence of aspirin, cyclooxygenase is acetylates yielding more omega-3 products. Aspirin
acetylation leads to the production of the more stable aspirin triggered epimer of resolvin d1 as shown.
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Chapter 2: Resolvins Decrease Hyperoxia Mediated Macrophage and Epithelial Cell
Interaction through Decreased Cytokine Secretion.

Abstract
Inflammation is a key hallmark of ALI and is mediated through ungoverned cytokine
signaling. One such cytokine, interleukin-1beta (IL-1β) has been demonstrated to be the most
bioactive cytokine in ALI patients. Macrophages are the key players responsible for IL-1β
secretion into the alveolar space. Following the binding of IL-1β to its receptor, “activated”
alveolar epithelial cells show enhanced barrier dysfunction, adhesion molecule expression,
cytokine secretion, and leukocyte attachment. More importantly, it is an important communication
molecule between the macrophage and alveolar epithelium. While the molecular determinants of
this inflammatory event have been well documented, endogenous resolution processes that
decrease IL-1β secretion and resolve alveolar epithelial cell activation and tissue inflammation
have not been well characterized. Lipid mediator Aspirin-Triggered Resolvin D1 (AT-RvD1) has
demonstrated potent pro-resolutionary effects in vivo models of lung injury; however, the
contribution of the alveoli to the protective benefits of this molecule has not been well documented.
In this study, we demonstrate that AT-RvD1 treatment lead to a significant decrease in oxidant
induced macrophage IL-1β secretion and production, IL-1β-mediated cytokine secretion, adhesion
molecule expression, leukocyte adhesion and inflammatory signaling.
THP-1 macrophages were treated with hydrogen peroxide and extracellular ATP in in the
presence or absence of AT-RvD1 (1000-.1nM). A549 alveolar-like epithelial cells were treated
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with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 (0.1 uM). Following treatment,
cell lysate and cell culture supernatants were collected for Western blot, qPCR and ELISA analysis
of pro-inflammatory molecules. Functional consequences of IL-1β induced alveolar epithelial cell
and macrophage activation were also measured following treatment with IL-1β ± AT-RvD1.
Results demonstrate that macrophages exposed to H2O2 and ATP in the presence of
resolvins show decreased IL-1β production and activity. A549 cells treated with IL-1β in the
presence of AT-RvD1 show a reduced level of proinflammatory cytokines IL-6 and IL-8. Further,
IL-1β-mediated adhesion molecule expression was also reduced with AT-RvD1 treatment, which
was correlated with decreased leukocyte adhesion. AT-RvD1 treatment demonstrated reduced
MAP-Kinase signaling. Taken together, our results demonstrate AT-RvD1 treatment reduced IL1β-mediated alveolar epithelial cell activation. This is a key step in unraveling the protective
effects of resolvins, especially AT-RvD1, during injury.

Introduction
Airway inflammation is a key hallmark in inflammatory lung disease such as acute lung
injury (ALI) and acute respiratory distress syndrome (ARDS) [1,2]. Following injury there is an
immediate release of proinflammatory mediators that serve to enhance the inflammatory response.
One of these inflammatory mediators, IL-1β is the most bioactive cytokine in the lungs of acute
lung injury patients [3]. IL-1β when secreted into the alveolar space (mainly by alveolar
macrophages), can act through its receptor IL-1R to upregulate mechanisms associated with
vascular and tissue remodeling, cytokine and chemokine expression, cellular attachment, as well
would repair [4-6]. In vitro murine models have shown that proinflammatory mediators play a key
role in the pathology of ALI [7-16]. IL-1β’s cellular binding partners include macrophages,
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endothelial cells, and the alveolar epithelium. The alveolar epithelium is a key regulator of the
proinflammatory and anti-inflammatory immune response.
The role of alveolar epithelium in inflammation is still not yet clear. Previously thought to
participate in surfactant production and barrier function, more studies are elucidating the role of
the alveolar epithelium in the inflammatory stage in response to proinflammatory mediators such
as IL-1β [17]. IL-1β serves to activate the alveolar epithelium and enhances the expression of
proinflammatory products such as cytokines, chemokines, adhesion molecules, and proinflammatory lipid mediators [3]. IL-1β binding has also been demonstrated to greatly diminish
the physical barrier properties and permeability of the alveolar epithelium through decreased tight
junction formation. More important to the persistent inflammation seen in ALI, the alveolar
epithelium plays an integral part in the recruitment of circulating leukocytes to the area of injury
[18,19]. The release of cytokines and expression of adhesion molecules by the activated alveolar
epithelium aids in the cytokine gradient and attachment points used by leukocytes to migrate into
the alveolar space. The consistent uncontrolled extravasation of these leukocytes, such as
neutrophils and monocytes, into injurious tissue is well documented to be a key event in the
development and progression of inflammatory lung disease [20-23]; however, the endogenous
resolution mechanisms and catabasic processes used by our body to resolve this imbalance has yet
to be clarified.
Resolution phase interaction products (resolvins) are lipid mediators derived from omega3 free fatty acids eicosapentanoic acid (EPA) and dicosahexanoic acid (DHA) [24-27]. In the
presence of aspirin, the aspirin-triggered forms of these lipid mediators are produced. Aspirintriggered resolvins, unlike the traditional resolvins, are resistant to oxidation and therefore are able
to show prolonged effect in comparison with traditional resolvins [25]. We have recently
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demonstrated the ability of aspirin triggered-resolvin D1 to enhance resolution of hyperoxic acute
lung injury (HALI) [28]. Resolvins show therapeutic promise in many different disease models
[24,25,29]; however, their role on the activation of the alveolar epithelium has not been elucidated.
In this study, we investigated the effects of aspirin-triggered resolvin D1 (AT-RvD1) on IL-1βinduced alveolar epithelial cell activation. The results indicate that AT-RvD1 modulates IL-1βmediated epithelial cell cytokine secretion and adhesion molecule expression. Further, our results
also demonstrated that AT-RvD1 also inhibit IL-1β-stimulated leukocyte adhesion. In addition,
AT-RvD1 decreased the activation of the p38 and ERK map kinase pathways, which are known
to be involved in the propagation of the inflammatory cascade in the alveolar epithelium. Our
results suggest that targeting the alveolar epithelium with resolvins, is a novel way to reduce
inflammation in the alveolar space.

Materials and Methods

Cell Culture
A549 cells are a human alveolar epithelial cell line derived from a human lung
adenocarcinoma patient. THP1 cells are a human monocytic cell line obtained from an acute
myeloid leukemia patient. Both cell lines were purchased from American Type Culture Collection
(ATCC, Manassas, VA). A549 cells and THP1 express all the components necessary to serve as
an effective cell line to model epithelial cell activation and monocyte adhesion, respectively. A549
cells were cultured in Dulbecco’s Modified Eagle Medium/F12 Nutrient mix (1:1 ratio, Gibco,
Grand Island, NY) complete with 10% fetal bovine serum (FBS, Gemini Biologicals, Sacramento,
CA) and 1% penicillin/streptomycin mixture (P/S, Gibco, Grand Island, NY). THP1 cells were
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used for cytokine, caspase and adhesion assays and were cultured in RPMI 1640 medium (Gibco,
Grand Island, NY) complete with 10% FBS (Gemini Biologicals, Sacramento, CA), 1% P/S and
1% sodium pyruvate (Gibco, Grand Island, NY). Both cell lines were maintained in a humidified
atmosphere at 37°C and 5% concentration. Cells were treated as mentioned in each section.

Cytokine Analysis
A549 cells were seeded in 12 well plates at a density of 0.5 x 106 cells/mL. Following 24
hr incubation to reach confluence, cells were serum starved for 6 hrs. After serum starvation A549
cells were treated with IL-1β (10 ng/mL, R&D Systems, Minneapolis, MN) in the presence or
absence of aspirin-triggered resolvin D1 (100 nM, AT-RvD1, Caymen Chemicals, Ann Arbor, MI)
for 6 hrs. Optimization of AT-RvD1 treatment was done using varying AT-RvD1 concentrations
in THP1 experiments (0.1-1000nM). Cells receiving AT-RvD1 were pretreated with AT-RvD1 for
30 minutes prior to addition of IL-1β or vehicle. THP-1 cells were seeded in 12 well plates at a
density of .5x106 cells per well. They were allowed to reach 85/%-90% confluence and then were
serum starved in the presence of priming agent phorbol-12-myristate-13-acetate (PMA, 10ng/mL).
Following treatment with PMA cells were primed with LPS to generate pro-IL-1β and then treat
with inflammasome activators ATP and hydrogen peroxide in the presence or absence of
docosahexaenoic acid, EPA, Resolvin D1 (RvD1), Resolvin D2 (RvD2) or AT-RvD1, all at
indicated dosages. All resolvins as well as DHA and EPA were obtained from Caymen Chemicals
(Ann Arbor, MI). Following the treatment of A549 and THP1 cells, supernatants were collected
and used for cytokine analysis via ELISA. ELISA for IL-1β (E-bioscience, San Diego, CA), IL-6
(E-bioscience, San Diego, CA) and IL-8 (R&D Systems, Minneapolis, MN) was performed
following the manufacturer’s instructions. Absorbance measurements were made using an
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absorbance plate reader (Biotek, Winooski, VT) and concentrations were obtained using
manufacturer provided standards. ELISA for active caspase-1 (R&D Systems, Minneapolis, MN)
in THP1 cells was performed using cell lysates and measured using absorbance readings.

Quantitative Real Time-PCR (qPCR)
A549 cells were seeded in 12 well plates at a density of 0.5 x 106 cells/mL. Following 24
hr incubation to reach confluence, cells were serum starved for 6 hrs. After serum starvation A549
cells were treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 (100 nM) for 6
hrs. Following treatment, cells were resuspended in Trizol (Invitrogen, Grand Island, NY) and
mRNA was harvested following the manufacturer’s instructions. 1 ug of RNA for each sample
was reverse transcribed into cDNA using the iSCRIPT cDNA synthesis kit (Bio-Rad, Hercules,
CA) according to the manufacturer’s instructions. Forward and reverse primers for 18S ribosomal
RNA as well as ICAM-1 were purchased from Integrated DNA Technologies (Coralville, IA).
Primers were used in a final concentration of 100 nM and assays were done in triplicate. Human
ICAM-1 and 18S ribosomal DNA were amplified using the following primers: ICAM-1F:5’-AGC
AAT GTG CAA GAA GAT AGC CAA-3’, ICAM-1R: 5’-GGT CCC CTG CGT GTT CCA CC3’, 18sF: 5′-TAA CGA ACG AGA CTC TGG CAT-3′ and 18sR: 5′-CGG ACA TCT AAG GGC
ATC ACA G-3′. qPCR was performed using the SYBR green master mix and CFX96 system (BioRad, Hercules, CA). Normalization of ICAM-1 expression was achieved by comparing the
expression of 18S ribosomal RNA for the corresponding sample.
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Epithelial Cell-Monocyte Adhesion Assay
The epithelial monocyte assay was performed as previously described with minor
modification [30]. Briefly, A549 cells were activated for 6 hrs with IL-1β in the presence or
absence of AT-RvD1. After treatment, the cells were washed with PBS and new media was added
to each well. 30 minutes prior to end of the 6 hr incubation, monocytes were loaded with calcein
AM dye (Life Technologies, Carlsbad, CA) and immediately added in the activated A549 cells.
After a 30 minute incubation period, unbound monocytes were washed away with PBS twice and
fluorescent images were taken.

Calcein AM Loading of Monocytes
Calcein AM was purchased from Invitrogen (Grand Island, NY) and diluted to a working
stock of 1 mM and stored in -20°C in light sensitive microcentrifuge tubes. Prior to the experiment,
THP1 cells were loaded with calcein AM at a final concentration of 10 uM for 30 minutes at
normal cell culture conditions in a humidified incubator. Following incubation, cells were washed
twice with PBS (without Ca2+ and Mg2+) and diluted at a final concentration of 0.5 x 106 cells/mL
prior to the addition of cells to the plates containing IL-1β activated A549 cells. 0.5 x 106 cells/mL
was added to each treatment for microscopy analysis. For plate reader analysis, 5 x 104 THP1 cells
were used.

Adhesion Assay for Alveolar Epithelial Cell-Monocyte Interaction
1 x 106 and 1 x 105 A549 cells were seeded in 12 well and 96 well plates, respectively.
After overnight incubation in complete medium, cells were serum starved for 6 hrs. After serum
starvation A549 cells were treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1
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(100 nM) for 6 hrs. Cells receiving resolvins were pretreated with AT-RvD1 for 30 minutes prior
to addition of IL-1β or vehicle. Following treatment, the aforementioned amount of THP1 cells
were added to each plate and co-incubated with A549 cells for 30 minutes. After incubation of
A549 cells with THP1 cells, the plate washed with PBS four times to ensure only bound THP1
cells were left in the plate. Microscopy (12 well plates) as well as relative fluorescence intensity
measurements (96 well plates) were used to analyze monocyte adhesion to treated A549 cells.
Images were taken and plates were read using excitation-emission spectra of Ex: 495nm/Em:
515nm.

Electric Cell-Substrate Impedance Sensing (ECIS)
A549 cells were seeded on 8W10E+ ECIS arrays (Applied Biophysics, Troy, NY) at a
density of 0.5 x 106 cells/mL. Cells were grown to a confluence as measured by a reading of 10
uF on the ECIS System (Applied Biophysics, Troy, NY). After achieving confluence, A549 cells
were subjected to serum starvation and were treated with IL-1β (10 ng/mL) in the presence or
absence of AT-RvD1 (100 nM) for 6 hrs. Cells receiving resolvins were pretreated with AT-RvD1
for 30 minutes prior to addition of IL-1β or vehicle. Resistance measurements were taken for a
period of 48 hrs. Three samples were used and 4 measurements were taken at each time point to
mitigate inter- and intra- sample variability. Culture medium served as the electrode and barrier
function was analyzed as a function of impedance of a cell-covered electrode. A 1-V, 4,000-Hz
alternating current signal was supplied through a 1-MΩ resistor to approximate a constant-current
source. ECMS 1.0 software (CET, Coralville, IA) was used to measure the in-phase voltage
resistance and capacitance. Epithelial barrier function of A549 cells was expressed as TER, which
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was normalized to a time-zero baseline. Epithelial monolayers that did not achieve a baseline TER
of 5,000 Ω or higher were excluded from this study.

Western Blot Analysis
As with ELISA, A549 cells were seeded in 12 well plates at a density of 0.5 x 106 cells/mL.
Following 24 hr incubation to reach confluence, cells were serum starved for 6 hrs. After serum
starvation A549 cells were treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1
(100 nM) for 6 hrs. Cells receiving resolvins were pretreated with AT-RvD1 for 30 minutes prior
to addition of IL-1β or vehicle. Following A549 cell treatment, cell lysates were collected using
RIPA Buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS, Thermo Scientific Pierce, Rockford, IL). After lysate extraction, protein concentration
was determined with a BCA assay (Thermo Scientific Pierce, Rockford, IL) following the
manufacturer’s specific instructions. 40 ug of protein was prepared, loaded, and separated on 8,
10, 12 or 15% SDS-PAGE gels (depending on the molecular weight of the protein of interest) and
then transferred onto a PVDF membrane (Thermo Scientific Pierce, Rockford, IL) using
electrophoresis. Membranes were blocked for 1 hr in 5% non-fat dry milk and then incubated with
total and phosphorylated p38, ERK 1/2, and SAPK/JNK antibodies (Cell Signaling, Boston, MA).
Membranes were then washed and probed with HRP-Conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA). HRP activity was detected using an enhanced
chemiluminescence (ECL) kit according to the manufacturer’s instructions (Thermo Scientific
Pierce, Rockford, IL).
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Statistical Analysis
All experiments were performed at least in three different experiments. Statistical
significance was analyzed using a paired student t-test and a 1-way analysis of variance where
applicable. A p- value less than 0.05 was considered to be statistically significant.

Results

Resolvins Inhibit IL-1β Secretion in THP1 Cells in a Dose Dependent manner
Macrophages are the major players involved in the initiation of the proinflammatory
cytokine cascade.

Macrophage mediated secretion of IL-1β, serves as an initiator of the

proinflammatory response and results in upregulation of proinflammatory genes on IL-1β target
cells [3]. Previously we have demonstrated that oxidant exposure leads to macrophage IL-1β
secretion, ultimately resulting in enhanced alveolar epithelial cell permeability [6].
In order to see whether resolvins can attenuate oxidant mediated IL-1β secretion in
macrophages, THP-1 monocytes were differentiated into macrophages and treated with hydrogen
peroxide and ATP, both well-known inducers of IL-1β secretion in macrophages (Fig 2.1). We felt
that this model of oxidant stress was physiologically relevant because our previous reports have
shown that hyperoxia signaling leads to enhanced extracellular ATP release which serves as an
adjuvant to oxidative stress to further enhance cytokine secretion [6]. Treatment with resolvin
precursors DHA and EPA resulted in a significant reduction of resolvin in IL-1β secretion
following oxidant-ATP treatment. Resolvins also leads to a significant decrease in IL-1β secretion
with AT-RvD1 having the most significant decrease. More importantly these resolvins were able
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to accomplish significant attenuation of IL-1β secretion at the low nanomolar ranges in comparison
to their parent fatty acids which achieved significane at the micromolar dosage (Fig 2.2).
To further confirm this we looked at resolvins ability to inhibit the activity of caspase-1,
the primary processing enzyme. Results showed that resolvins RvD1 and AT-RvD1 show
significant inhibition of caspase-1 activity following oxidant-ATP mediated activation. Taken
together these results highlight an important role for resolvins in decreasing the release of early
macrophage mediated cytokine IL-1β in oxidant related injury.

Resolvin Treatment Results in Decreased Macrophage Induced Alveolar Epithelial
Cytokine Secretion.
Our previous reports have demonstrated that oxidant mediated macrophage cytokine
secretion results in increased permeability of alveolar epithelial cells. Previous reports have also
highlighted that this interaction between the macrophages and epithelial cells are cytokine
dependent. Since polarization of epithelial cells leads to an enhanced inflammatory state and is an
important part of the inflammatory cascade, we wanted to assess resolvins’ ability to blunt the
macrophage to epithelial cell interaction. We also wanted to assess whether the protective role was
mediated through reduced IL-1β. To test this THP-1 monocytes were differentiated and treated
with ATP and hydrogen peroxide in the presence or absence of resolvins RvD1 and AT-RvD1.
Supernatants were collected and used to treat A549 cells for 1 hour. Following treatment
supernatant was collected and analyzed for proinflammatory mediator and neutrophil
chemoattractant IL-8. Results reveal that both RvD1 and AT-RvD1 blunted the ability of
supernatant from oxidant-ATP treated cells to induce A549 cells to secrete IL-8. Since AT-RvD1
showed a more significant increase in macrophage studies and is more resistant to enzymatic
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cleavage, we chose to use it as our primary molecule for resolvin investigation going forward in
this dissertation.

AT-RvD1 Decreases IL-1β-mediated Proinflammatory Cytokine Release in Alveolar
Epithelial Cells
Alveolar epithelial cells are activated when in the presence of proinflammatory molecules
such as IL-1β [3]. Following activation, secretion of proinflammatory mediators such as IL-8 and
IL-6 serves to propagate the inflammatory signal to the lung interstitium and vasculature [6,31].
To determine whether AT-RvD1 inhibited the rate of proinflammatory cytokine secretion by
alveolar epithelial cells, A549 cells were grown and the secretion of IL-6 and IL-8 were
investigated. As shown in Fig. 2.5A and 1B, A549 cells treated with IL-1β (10 ng/mL) display an
increase in IL-6 and IL-8 secretion. However, this increase is attenuated for both cytokines in the
presence of AT-RvD1 (100 nM). No significant difference was observed between the resolvin and
control groups. While the release of both cytokines were significantly dampened with resolvin
treatment, resolvins were able to reduce the IL-1β-mediated IL-6 (Fig. 2.5B) by greater than 60%
(p < 0.001) in comparison to IL-1β treatment alone.

AT-RvD1 Attenuates IL-1β-induced Adhesion Molecule Expression in Alveolar
Epithelial Cells
Proinflammatory cytokines such as IL-1β and IL-6 have been demonstrated to induce the
expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1, CD54)
[32,33]. ICAM-1 is a transmembrane protein that plays an important role in the transepithelial
migration of leukocytes into the epithelium. We hypothesized that the reduced cytokine secretion
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would result in decreased ICAM-1 expression. To investigate the effect of resolvins on IL-1βinduced A549 ICAM-1 expression, A549 cells were treated with IL-1β (10 ng) in the presence or
absence of aspirin-treated resolvin D1 (100 nM). Following IL-1β Treatment, ICAM-1 expression
increased to its maximal value. 10 minute pretreatment of A549 cells with AT-RvD1 prior to IL1β led to a 35% decrease (p < 0.05) in ICAM-1 expression (Fig. 2.6).

AT-RvD1 Inhibits IL-1β-mediated Monocyte and Alveolar Epithelial Cell Adhesion
Circulating leukocytes extravasate out of vasculature and migrate into damaged tissue
following acute injury. This is aided by the secretion of proinflammatory molecules such as IL1β, IL-8, and IL-6 [34]. Once out of the vasculature, adhesions molecules such as ICAM-1 play a
key role in the extravasation into the injured lung tissue [35]. Since resolvins decreased cytokine
and ICAM-1 secretion and expression, respectively; we hypothesized that resolvins would
decrease leukocyte adhesion to alveolar epithelial cells. To investigate this, A549 cells were
treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 (100 nM). Following IL1β treatment, calcein AM loaded THP1 monocytes were loaded into the wells containing A549
cells and co-cultured for 30 minutes. Image analysis shows that monocyte adhesion (as seen with
green fluorescent dots) was significantly enhanced with IL-1β treatment alone in comparison to
control. Monocyte adhesion was significantly diminished when A549 cells was pretreated with
AT-RvD1 (Fig 2.7A). Treatment with AT-RvD1 alone did not significantly enhance monocyte
adhesion. In a separate experiment, the adhesion assay was reproduced in 96 well plates and
relative fluorescent intensity was measured to further quantify our results. Resolvin treatment
resulted in greater than 50% reduction in IL-1β-mediated THP1-A549 cell adhesion in comparison
to cells that were treated with IL-1β alone (Fig. 2.7B). This further confirmed the difference seen

50

in the fluorescence microscopy analysis. In an attempt to mitigate the effect of cellular variability,
only confluent monolayer following IL-1β treatment was used for the adhesion assay. These
monolayers are shown in the bright field images (Fig. 2.7A). We did not detect a difference in
monolayer consistency among the groups following IL-1β treatment.

AT-RvD1 Fails to Rescue Barrier Dysfunction In Alveolar Epithelial Cells
Alveolar epithelial cells form alveolar capillary barrier between the alveolar epithelium
and the lung microvasculature. This barrier function of the alveolar epithelium also preserves the
microenvironment of the alveoli and alveolar capillaries. Disruption of this barrier in the presence
of proinflammatory mediators such as IL-1β leads to alveolar thickening, pulmonary edema, and
diminished gas exchange [3,7,15,36-38]. To assess the effect of resolvins on IL-1β-induced barrier
dysfunction, transepithelial permeability (TER) was analyzed using electric cell-substrate
impedance sensing (ECIS). A549, seeded in ECIS electrode arrays, were treated with IL-1β (10
ng/mL) in the presence or absence of aspirin-triggered resolvin D1 (100 nM) (Fig. 2.8). TER was
recorded by the ECIS system for 48 hrs. Both resolvin alone and control treatment showed a small
decrease in TER after 48 hrs. There was no significant difference in TER between the groups
treated with IL-1β and resolvins in comparison to those treated with IL-1β alone. Resolvin
pretreatment did slightly improve the decrease in barrier resistance caused by IL-1β in comparison
with IL-1β treatment alone. Resolvins RvD1 and AT-RvD1

AT-RvD1 Attenuates IL-1β-induced MAP Kinase Phosphorylation
Mitogen activated protein kinases (MAPKs) are important regulators of the immune
response in many myeloid and non-myeloid lineages such as alveolar epithelial cells. When
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activated these proteins play an important role in activating transcription factors that are necessary
for transcription of proinflammatory events following injury such as cytokine production, barrier
dysfunction, and adhesion molecule expression. The binding of IL-1β to its receptor, (IL-1R), leads
to the activation of various pathways including those of MAPKs. Since we observed a change in
IL-6 and IL-8 secretion as well as a decrease in ICAM-1 expression, we hypothesized that resolvins
decrease the inflammatory effects of alveolar epithelial cells through decreased MAPK activation.
To test this, A549 cells were treated with IL-1β (10 ng/mL) in the presence or absence of aspirintriggered resolvin D1 (100 nM). Following treatments, cell lysates were collected for Western blot
analysis of p38, ERK 1/2, and SAPK/JNK MAPK. These three MAPKs play a key role in
propagating the inflammatory signal following IL-1β stimulation. AT-RvD1 pretreatment
decreased p38 and to a lesser extent ERK phosphorylation at 5 and 10 minutes (Fig 2.9 A-B). No
change was observed between the control and AT-RvD1 alone samples. AT-RvD1 pretreatment
failed to inhibit the phosphorylation of SAPK/JNK following IL-1β treatment at both 5 and 10
minutes. Taken together, these results suggest that resolvins modulate alveolar epithelial activation
through a decrease in p38 and ERK 1/2 MAPKs.

Discussion
IL-1β is known to be one of the earliest and most bioactive cytokines secreted following
acute injury [3]. Release of this potent proinflammatory molecule causes up regulation of
proinflammatory pathways on epithelial and endothelial cells leading to cytokine secretion
[6,34,39]. This cytokine secretion is key to propagating the inflammatory signal beyond the
airways and into the vasculature. We therefore investigated the effect of resolvins to curb
inflammatory cytokine IL-6 and chemokine IL-8/CXCL8. These mediators, through paracrine, and
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autocrine signaling play a key role in persistence of the inflammatory phenotype [40-44]. We
demonstrated the ability of resolvins to significantly curb the secretion of these proinflammatory
cytokines. Further, we show that this decrease in cytokines by AT-RvD1 also correlated with a
decrease in the expression of intercellular adhesion molecule-1 (ICAM-1). Once secreted into the
extracellular milieu these inflammatory cytokines serve to upregulate important adhesion
molecules that are used by migrating leukocytes to enter into the injured tissue and further prolong
the inflammatory cycle [45]. These leukocytes such as neutrophils and monocytes are rich in
proinflammatory mediators and add to the multifunctional inflammatory sequence that is not easily
overcome naturally in inflammatory lung diseases. Our results tether AT-RvD1 to reduced
proinflammatory molecules; however, we did not know the functional consequences of this
reduced pro-inflammatory profile.
Since administration of AT-RvD1 significantly decreased the factors that play a role in
monocyte recruitment such as adhesion molecule expression and cytokine secretion, we wanted to
investigate IL-1β-induced alveolar epithelial cell-leukocyte interaction through adhesion.
Monocytes and neutrophils serve as key first responders to the site of injury and can also be
implicated as culprits in the overactive immune response. Inflammatory monocytes in the presence
of inflammatory mediators such IL-1β, migrate into the tissue and differentiate into macrophages
and ultimately foam cells in early injury. These differentiated monocytes have a much longer
lifespan than infiltrating neutrophils and serve to consistently reinvent the proinflammatory signal
in uncontrolled inflammation seen in ALI. Therefore, we wanted to investigate the effect of
resolvins on the attachment to an IL-1β stimulated alveolar epithelium, citing the fact that IL-1β
induces leukocyte attachment through adhesion molecule upregulation. In line with its effects on
cytokine secretion and ICAM-1 expression, AT-RvD1 significantly diminished the effect of IL-1β
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to induce alveolar epithelial cell and monocyte adhesion. This correlates with previous reports that
demonstrate resolvins as key mediators of leukocyte influx and barrier resistance. By our hands,
however, we were not able to show an improvement in IL-1β-mediated alveolar epithelial barrier
dysfunction with resolvin treatment.
MAP kinases are key molecules found in a variety of cells involved in the immune
response. While different MAP kinases are important in different cells, the three predominant map
kinases (p38, ERK, and SAPK/JNK) have all been shown to play a role in epithelial inflammatory
signaling. AT-RvD1 treatment in accordance with previously reported effects of other resolvins
on MAPKs showed a significant decrease in p38 and ERK phosphorylation and subsequent
activation. However, we did not observe a change in SAPK/JNK signaling. P38 and ERK have
been shown to be responsible for the production of proinflammatory cytokines following IL-1β
stimulation. They have also been shown to be involved in adhesion molecule expression. Our
results with resolvin pretreatment suggest a protective mechanism for resolvins through regulation
of MAP kinase activity.
Inflammatory lung disorders such as cystic fibrosis or ALI feature significantly enhanced
levels of proinflammatory cytokines as well as aggressive infiltration of leukocytes into the injured
tissue. While alveolar macrophages play a key role in the secretion of early mediators such as IL1β, the alveolar epithelium is an important source of inflammatory mediators as well and a key
site of immune cell tissue interaction following injury. Secretion and binding of IL-1β leads to
barrier dysfunction, cytokine/chemokine secretion, and barrier dysfunction. Omega-3 (ω-3) free
fatty acids have shown beneficial effects in vitro at curbing the immune response. Ω-3 derivatives
termed ‘resolution-phase interaction products’ have also been demonstrated to curb the
inflammatory phenotype seen in diseases such as COPD and aspiration pneumonia-induced ALI.
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In this article, we demonstrate for the first time the protective effects of aspirin-triggered resolvin
D1 (AT-RvD1) in diminishing the inflammatory phenotype of these cells following IL-1β
stimulation. Together, this report supports previous studies that show that resolvins are potent
potential therapeutic for inflammation seen in ALI. More importantly, these experiments
demonstrate a novel role of AT-RvD1 in the inhibition of IL-1β-induced alveolar epithelial cell
activation.
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Figures

Figure 2.1: H2O2 and ATP Treatment Results in Enhanced IL-1β Secretion in THP-1
Macrophages. In order to reconstruct a physiologically relevant model of hyperoxia induced
macrophage secretion, primed THP-1 macrophages were treated with ATP (5µM), H2O2(10mM)
or combination of both ATP and THP1 for 1hr. IL-1β released into the cell culture supernatant
was analyzed. One way ANOVA was used with a tukey post-hoc test, where a p-value <.05 was
deemed statistically significant. Significance: * = p< .05 , ** = p< .01, *** = p< .001, vs no
treatment control.
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Figure 2.2: Omega-3 Treatment results in decreased hyperoxia induced IL-1β secretion in
THP1 macrophages. In order to assess the therapeutic effects of omega-3 fatty acids DHA and
EPA as well as resolvin metabolites on IL-1β secretion, primed THP-1 macrophages were treated
with ATP (5µM), H2O2(10mM) or combination of both ATP in the presence or absence of EPA,
DHA, RvD1 and AT-RvD1 at indicated doses for 1hr. IL-1β release into the cell culture
supernatant was analyzed. One way ANOVA was used with a tukey post-hoc test, where a p-value
<.05 was deemed statistically significant. Significance: * = p< .05 , ** = p< .01, *** = p< .001, vs
no treatment control.
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Figure 2.3: Resolvin Treatment results in decreased hyperoxia caspase-1 activation in THP1
macrophages. In order to assess the role of RvD1 and AT-RvD1 on IL-1β processing enzyme
caspase-1, primed THP-1 macrophages were treated with ATP (5µM), H2O2(10mM) or
combination of both ATP in the presence or absence of RvD1 and AT-RvD1 at indicated doses for
1hr. Activated caspase-1 into the cell culture supernatant was analyzed by ELISA. One way
ANOVA was used with a tukey post-hoc test, where a p-value <.05 was deemed statistically
significant.
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Figure 2.4: Resolvin Treatment results in decreased hyperoxia caspase-1 activation in THP1
macrophages. In order to decipher whether resolvin mediated reduction in hyperoxia induced IL1β in macrophages leads to a change in epithelial cell activation, primed THP-1 macrophages were
treated with ATP (5µM) + H2O2 (10mM) in the presence or absence of RvD1 (100nM) and ATRvD1 (100nM) ) at indicated doses for 1hr. Secretion of IL-8 into the cell culture supernatant was
analyzed by ELISA. One way ANOVA was used with a tukey post-hoc test, where a p-value <.05
was deemed statistically significant.
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Figure 2.5: Aspirin-Triggered Resolvin D1 Attenuated IL-1β-induced Cytokine/Chemokine
Secretion. A549 cells were seeded at a density of 0.5 x 106 million cells per well in 12 well plates.
When cells reached confluence, they were then serum starved and treated with IL-1β (10 ng/mL)
in the presence or absence of aspirin-triggered resolvin D1 (AT-RD1, 100 nM) for 6 hrs. Following
treatment, cell culture supernatants were collected and the presence of (A) IL-8 and (B) IL-6 levels
were analyzed by ELISA. A student t-test was used to determine statistical significance with p <
0.05 being statistically significant. ND = Not detected, limit of detection 2 pg/mL.
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Figure 2.6: Aspirin-Triggered Resolvin D1 Attenuate IL-1β-induced Intercellular Adhesion
Molecule-1 Expression. A549 cells were seeded at a density of 0.5 x 106 million cells per well in
12 well plates. When cells reached confluence, they were then serum starved and treated with IL1β (10 ng/mL) in the presence or absence of aspirin-triggered resolvin D1 (AT-RD1, 100 nM) for
6 hrs. Following treatment, cells were lysed in Trizol and mRNA was extracted. Complimentary
cDNA was produced and qPCR analysis was performed utilizing primers specific for ICAM-1.
Statistical significance was determined using a standard student t-test with p < 0.05 being
statistically significant.
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Figure 2.7: Aspirin-Triggered Resolvin D1 Attenuated IL-1β-mediated leukocyte-epithelial
cell adhesion. A549 cells were seeded in A) 12 well at a density of 0.75 x 106 or B) 96 well plates
at a density of 0.1 x 106 cells per well. Following serum starvation the cells were treated with IL1β (10 ng/mL) in the presence or absence of aspirin-triggered Resolvin D1 (100 nM) for 6 hrs.
Following IL-1β treatment, calcein AM loaded THP1 cells were co-incubated with the alveolar
epithelial cells for 30 minutes. Unbound attached monocytes were washed away with media and
leukocyte attachment was observed via (A) fluorescent microscopy and (B) quantified with a
reading of mean fluorescence intensity at Ex: 495 Em: 515. Statistical significance was measured
with a one-way ANOVA with p < 0.05 being statistically significant.
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Figure 2.8: Aspirin-Triggered Resolvin D1 does not rescue barrier function in IL-1β-treated
A549 cells. A549 cells were seeded in 8 well 8W1E ECIS arrays at a density of 5 x 104 cells/mL.
When cells reached confluence, they were treated with IL-1β (10 ng/mL) in the presence or
absence of AT-RD1 (100 nM). Barrier resistance was recorded over 48 hrs using ECIS. To
eliminate variability; samples were treated, duplicated, and recorded 4 times at each time point.
Significance was measured with a one-way ANOVA with p < 0.05 being statistically significant.
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Figure 2.9: Resolvins regulate IL-1β-induced p38 and ERK 1/2 activity in alveolar epithelial
cells. A549 cells were seeded at a density of 0.5 x 106 million cells per well in 12 well plates. When
cells reached confluence, they were then serum starved and treated with IL-1β (10 ng/mL) in the
presence or absence of aspirin-triggered resolvin D1 (AT-RvD1, 100 nM) for 6 hrs. Following
treatment, cells were harvested and lysed with RIPA buffer. Western blot analysis was performed
and the samples were probed for the presence of total and phosphorylated (A) p38 and (B) ERK
1/2 MAPKs using enhanced chemiluminescence.
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Figure 2.10: AT-RvD1 is a double edged sword that blunts macrophage and epithelial
communication through reduced cytokine signaling. Hyperoxia exposure leads to an enhanced
secretion of proinflammatory cytokines, with IL-1β being the most bioactive for ALI patients. IL1β Secretion results in alveolar epithelial cell activation which is hallmarked by enhanced barrier
function, cytokine secretion, and adhesion molecule expression. We found that AT-RvD1 was able
to interrupt the macrophage to alveolar communication through the blockage of IL-1β signaling.
Upon treatment of alveolar epithelial cells with IL-1β, there was an increase in inflammatory
activation, which was significantly attenuated with AT-RvD1 treatment.
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Chapter 3: Hyperoxic Acute Lung Injury Resolution is
Enhanced by Aspirin Triggered Resolvin D1 Treatment in vivo.

Abstract
Acute lung injury (ALI), which presents as acute respiratory failure, is a major clinical
problem that requires aggressive care, and patients that require prolonged oxygen exposure are at
risk to develop this disease. Although molecular determinants of ALI have been reported, the
molecules involved in disease catabasis associated with oxygen toxicity have not been well
studied. It has been reported that lung mucosa is rich in omega-3 fatty acid dicosahexanoic acid
(DHA), which has anti-inflammatory properties. Aspirin triggered-resolvin D1 (AT-RvD1) is a
potent proresolution metabolite of DHA which can curb the inflammatory effects in various
acute injuries, yet the effect of AT-RvD1 on hyperoxic acute lung injury (HALI) or in the
oxygen toxicity setting in general has not been investigated. The effects of AT-RvD1 in HALI
were determined for the first time in 8-10 week old C57BL/6 mice which were exposed to
hyperoxia (≥95% O2) for 48hrs. Mice were either given AT-RvD1 (100ng) in saline or a saline
vehicle for 24hrs in normoxic (≈21% O2) conditions following hyperoxia. Lung tissue and
bronchoalveolar lavage (BAL) fluid were collected for analysis associated with proinflammatory
signaling and lung inflammation. AT-RvD1 treatment resulted in reduced oxidative stress,
increased glutathione production and significantly decreased tissue inflammation. AT-RvD1
treatment also significantly reduced the lung wet/dry ratio, protein in BAL fluid, and decreased
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apoptotic and NFκB signaling. These results show that AT-RvD1 curbs oxygen induced lung
edema, permeability, inflammation, and apoptosis and is thus an effective therapy for prolonged
hyperoxic exposure in this murine model.

Introduction
Acute lung injury (ALI) is a major clinical problem that contributes to the death of
greater than 70,000 people annually in the United States (1, 2). ALI is an acute respiratory
syndrome hallmarked by a breakdown of the alveolar-capillary membrane barrier, lung edema
formation, pulmonary epithelial cell death, and an acute inflammatory response. While the
pathogenesis is heterogeneous, extensive studies have not led to an effective treatment (3).
Hyperoxic therapy remains the major form of supportive care for patients with decreased
respiratory function such as those who suffer from ALI. However, prolonged hyperoxic exposure
(greater than 65% O2), can lead to further exacerbation of lung symptoms and cause hyperoxic
acute lung injury. Murine models of hyperoxia display similar symptoms and pathology to those
seen in humans (4-8). Toxic concentrations of oxygen lead to generation of reactive oxygen
species which lead to a redox imbalance and in turn causes alveolar flooding, inflammation,
apoptosis and necrotic death of alveolar epithelial cells (9, 10). Excessive hyperoxemia also
leads to upregulation of proinflammatory mediators such as IL-1β (11). It may also lead to
activation of the apoptotic signaling cascades triggered by the enhanced expression of
proapoptotic proteins of the BH3-only BCL-2 protein family (12, 13). While several laboratories,
including our own, have previously reported the molecular determinants that may play a role in
HALI development (11, 13-15), the process of lung resolution and repair has not been well
studied, especially in the oxidant toxicity setting.
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HALI is usually self-limiting and resolves with minimal fibrosis in comparison to other
models of ALI (16, 17); however, the molecular mechanisms involved in tissue catabasis has not
been elucidated. Polyunsaturated fatty acid (PUFA) supplements significantly improve
circulating anti-inflammatory biomarkers, reduce inflammatory cytokine levels, and promote gas
exchange in adolescent and adult lung injury patients (18, 19). The PUFAs generated following
injury serve as key mediators of inflammation. Of these fatty acids, omega-3 derivatives, referred
to as resolution phase interaction products (resolvins), have drawn considerable interest for their
potential to resolve acute injury in various disease models (20-28). These lipid mediators are
anti-inflammatory, promote tissue homeostasis, and help revert injured and inflamed tissue to a
normal state. Resolvins, discovered in resolving inflammatory exudates in mice, are classically
synthesized through a primarily lipoxygenase driven pathway. In the presence of aspirin,
however, more stable and less enzymatically susceptible “aspirin-triggered” epimeric forms are
generated through aspirin-induced cyclooxygenase-2 acetylation (21).
Previous reports show anti-inflammatory and pro-resolving roles of Aspirin-Triggered
Resolvin D1 (7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoic acid, AT-RvD1),
in the reduction of other sterile injuries such as aspiration pneumonitis in mice (26, 27).
However, oxidant stress as a result of this study was found to be very low and thus, the ability of
AT-RvD1 to alleviate inflammation and injury resulting from oxygen toxicity has not been
properly investigated. Therefore, in this study we investigated the effects of AT-RvD1 on the
resolution of HALI. While 24 hour treatment with vehicle allowed for modest resolution,
treatment with AT-RvD1 following hyperoxia exposure resulted in a significant increase in
decreased oxidative stress, increased resolution of tissue inflammation, enhanced antioxidant
production, enhanced clearance of cellular infiltration and reduction of edema formation and
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alveolar protein leak. AT-RvD1 treatment also resulted in a marked decrease in proinflammatory and apoptotic signaling. Thus results also suggest that AT-RvD1 enhances HALI
resolution.

Materials and Methods

Animals
The University of South Florida Institutional Animal Care and Use Committee approved
the animal protocol. Six to eight-week-old C57BL/6 WT mice (Harlan Laboratories,
Indianapolis, IN) were used to conduct all in vivo experiments. They were housed in isolated
cages on an automatic 12-hr light to dark cycle at room temperature (25°C). Water and standard
food were available ad libitum.

Murine Hyperoxic Injury Resolution Model
Lung injury was induced using a murine hyperoxia model as previously described (9, 29).
Mice, in cages, were placed in an airtight chamber (70 x 50 x 50 cm) and exposed to hyperoxic
conditions (95-100% O2) for 48 hrs, sufficient to induce moderate to severe acute lung injury
(30). An oxygen regulator was used to monitor and maintain the chamber’s atmospheric
conditions (BioSpherix, NY, USA). To assess the impacts of AT-RvD1 on hyperoxic lung injury
resolution, mice were kept under normoxic conditions (21% O2) following hyperoxic exposure
and given either AT-RvD1 (Fig. 3.1A, 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-
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docosahexaenoic acid, 0.5-0.05μg, 95% purity, no LPS was detected, Caymen Chemicals, Ann
Arbor, MI) or vehicle (1% ethanol in saline) to serve as an indicator of normal injury resolution
(control group). 100 µl of AT-RvD1 or saline was injected via the i.v or i.p. route of
administration. Mice were euthanized 24 hrs after treatment and tissue samples and
bronchoalveolar lavage (BAL) fluid were collected in separate experiments. The experimental
outline is shown in schematic form in fig. 3.1B

Enzyme Linked Immunosorbant Assay (ELISA)
Cytokines in BAL fluid were collected and analyzed as described previously (31). The
levels of proinflammatory mediators IL-1β, TNF-α, IL-6 keratinocyte-derived chemokine (KC)
and monocyte chemoattractant protein 1 (MCP-1) were measured by ELISA according to the
manufacturer’s instructions (Affymetrix ebioscience, San Diego, CA). Levels of TNF-α
following hyperoxia were not detectable in both AT-RvD1 and vehicle groups. Myeloperoxidase
from lung tissue was also assessed via ELISA according to manufacturer’s instructions (R&D
Systems, Minneapolis, MN)

Immunohistochemical Staining on Lung Tissue Sections
Immunohistochemical staining (IHC) was performed on paraffin embedded lung tissue
sections as previously described and according to the manufacturer’s instructions (32). Lung
tissue sections were incubated with 20 μg/ml of proteinase K for 40 minutes at 37°C following
deparaffinization. Tissue sections were then blocked with 3% hydrogen peroxide in PBS
followed by incubation with goat anti-mouse active caspase-3 antibody (Abcam, Cambridge,
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England, UK) overnight at 4°C. The sections were subsequently incubated with anti-rabbit
horseradish peroxidase conjugate for 60 min at 37°C. Images were taken to assess cellular
apoptosis following the addition of 3, 3′-diaminobenzidine.

Glutathione
Following euthanization, lung tissues of mice from each group were harvested (N=4).
Total GSH was measured using GSH detection kit from Enzo Life Sciences (Farmingdale, NY)
as previously described (33).

mRNA Quantification
Following euthanasia, lung tissue samples were collected and flash frozen in liquid
nitrogen as previously described (30). Total mRNA was harvested from lung tissues and
converted to cDNA using the iScript cDNA Syntehsis Kit (Bio-Rad, Hercules, CA). The
following primers were used and synthesized through Integrative DNA Technologies: Nrf2
forward 5′-TCTCCTCGCTGGAAAAAGAA-3′ Nrf2 reverse 5′AATGTGCTGGCTGTGCTTTA-3′; 18s forward 5´TTGACGGAAGGGCACCACCAG 3´ and
18s reverse: 5´CTCCTTAATGTCACGCACGATTTC 3´). Quantitative RT-PCR was performed
as previously described (34).
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Preparation of Protein Extract
Following euthanasia, lung tissue samples were collected and flash frozen in liquid
nitrogen as previously described (30). The protein extraction samples were thawed and
homogenized in protein extraction buffer (20 mM, 125 Tris HCl, pH 7.4, 150 mM NaCl, 0.5%
Triton X-100) supplemented with phosphatase and protease inhibitor cocktail (Sigma Aldrich,
St. Louis, MO). Samples were homogenized on ice for 15 seconds and then sonicated. Samples
were centrifuged at 12,000 rpms for 15 minutes at 4°C to extract protein from the sample after
two freeze thaw cycles. Supernatants containing protein were collected, quantified, aliquoted and
stored for future use. For NFκB analysis, the nuclear extractions were prepared utilizing the NEPER Nuclear and Cytoplasmic Extraction (Thermo-Scientific, Rockford, IL) according to
manufacturer’s instructions.

Western Blot Analysis
Lung protein was extracted from tissue using the aforementioned methods. Samples were
mixed with lamelli buffer, denatured (95°C for 5 minutes), and loaded (40-50 μg) onto a 10%
SDS-PAGE gel prior to gel electrophoresis. Once the gels were completed, they were transferred
onto a PVDF membrane (Thermoscientific, Rockford, IL) using the Mini-Protean apparatus
(Bio-Rad, Hercules, CA). Membranes were then blocked in 5% non-fat dry milk for 1 hr and
probed at 4°C overnight for antibodies directed against mouse phosphor-NFκB (p65 subunit),
total NFκB (p65 subunit) in the nuclear fraction and phosphor-BAD, total BAD, BIM, phosphorp38, total p38, phosphor-p44/42, total p44/42, phosphor-SAPK/JNK, total SAPK/JNK, and
active caspase-3 in lung lysate overnight. Membranes were probed with anti-rabbit secondary
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antibody conjugated to HRP (Jackson ImmunoResearch Laboratories, West Grove, PA)
following overnight incubation. Protein expression was detected using enhanced
chemiluminescent Western blotting substrate (Thermo Scientific-Pierce, Rockford, IL) following
secondary antibody exposure. All primary antibodies were purchased from Cell Signaling
Technology (Danvers, MA) with the exception of active-caspase-3 (Abcam, Cambridge,
England, UK).

Lung Mechanics Analysis
In a separate experiment, mice were anesthetized with ketamine-xylazine and placed on a
small rodent mechanical ventilator and respiratory mechanics apparatus (SCIREQ, Montreal,
Canada). The lung resistance of mice in each group (n = ≥8 in each group) was measured
following ventilation.

Statistical Analysis
Statistical analysis was performed using the Graphpad Prism software (GraphPad
Software, Inc. San Diego, CA). Comparison of samples between two groups was completed
using a standard Student t-test. Comparison of samples in three or more groups was calculated
using a one-way ANOVA with a Tukey post-hoc test to measure significance between groups. Pvalues for all tests were calculated and labeled where significant. A p-value < 0.05 was
considered significant and all t-tests were two-tailed.
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Results

AT-RvD1 Treatment Following Hyperoxic Injury Leads to Decrease Lung
Resistance and Oxidative Stress
Oxidative stress is the key insult of the HALI model and thus the ability of AT-RvD1 to
resolve oxidative stress in lung tissue warrants investigation. Lipid peroxidation is a welldocumented indicator of oxidative stress (35-37). To test the ability of AT-RvD1 to reduce lipid
peroxidation following hyperoxic injury, C57/BL6 mice were given AT-RvD1 (0.5-0.05µg)
following 48 hr hyperoxia exposure. BAL fluid was collected and a TBARs assay was performed
(Fig. 3.1C). Results reveal that AT-RvD1 treatment following hyperoxic injury leads to a greater
than 75% decrease in lipid peroxidation as measured with the TBARs assay, in comparison to the
vehicle group, which only showed a 25% decrease in lipid peroxidation. These results also
suggest that AT-RvD1 provides significantly enhanced resolution of oxidative stress following
HALI at an optimal dose of 0.1µg. Antioxidant imbalance is a well-documented result of
oxidative stress (33, 38-43). Antioxidant-oxidant imbalance leads to antioxidant depletion and
proinflammatory reactive oxidant-antioxidant complexes (36, 44-47). Our results reveal that
mice treated with AT-RvD1 have significantly higher glutathione in lung tissues as well as
significantly enhanced expression of antioxidant transcriptional regulator Nrf2 (Fig 3.10).
Previous reports point to increased lung resistance as a result of oxidative stress (38, 48, 49). To
further assess the functional contributions of AT-RvD1 (0.2-0.05µg) to hyperoxia-induced
impairment of lung mechanics, lung resistance was measured using the SCIREQ flexiVent
apparatus (Fig. 3.1D). Surprisingly, saline treatment resulted in a small increase in lung
resistance following hyperoxia exposure; however, this increase was not statistically significant.
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This phenomenon was curtailed with AT-RvD1 treatment following injury. AT-RvD1 treatment
resulted in significantly reduced lung resistance in comparison to both the hyperoxia and the
hyperoxia followed by vehicle treatment groups. The decreased lung resistance in response to
AT-RvD1 treatment points to improved resolution of HALI.

AT-RvD1 Treatment Following Injury leads to Decreased Hyperoxia-Induced
Leukocyte Infiltration
Previous reports have alluded to the increased airway resistance as a key indicator airway
inflammation and an increase in inflammatory cell infiltrate (50-52). Recruitment of leukocytes
to the injured area is a key hallmark of HALI, and reduction of this infiltration marks a key event
in injury resolution. C57/BL6 mice were given AT-RvD1 (0.1 µg, I.V.) following 48 hr
hyperoxia exposure to determine the capacity of AT-RvD1 to reduce leukocyte infiltration
following hyperoxic injury. The leukocyte accumulation in the BAL fluid was analyzed using
total and differential cell counts (Fig. 3.2). Images were taken of BAL fluid cells that were
cytospun onto microscope slides and differentially stained (Fig. 3.3A-E). Results revealed that
mice treated with AT-RvD1 had a three-fold decrease of total cells in the BAL fluid compared to
mice treated with the vehicle (Fig. 3.2A). Differential counts of leukocytes revealed that both
macrophages and neutrophils were significantly decreased in the AT-RvD1 group, with a greater
than 10-fold decrease in neutrophil accumulation (Fig 3.2B, 3.2C, and black arrows in Fig 3.3AE). AT-RvD1-treated mice show a significant decrease in comparison to mice treated with
vehicle following the injury in neutrophil percentage (< 3%) and a similarly significant increase
in macrophage percentage (> 97%) among leukocyte subsets in BAL fluid (Fig. 3.2D). Results
further show that KC, a neutrophil chemokine, is significantly decreased in the BAL of mice
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treated with AT-RvD1 following injury (Fig. 3.3F). Myeloperoxidase, a peroxidase which is
abundantly expressed in neutrophils, was significantly decreased in AT-RvD1-treated mice in
comparison to vehicle control (Fig. 3.3G). Altogether, results indicate that AT-RvD1 treatment
following hyperoxic injury significantly reduces accumulation of leukocytes into the injured
area, especially neutrophils.

AT-RvD1 Attenuates Hyperoxia-Induced Lung Inflammation and Permeability
Influx of inflammatory cells is a hallmark of HALI and an indicator lung inflammation
(1). It was hypothesized that AT-RvD1 treatment would resolve hyperoxia-induced lung
inflammation, since mice treated with AT-RvD1 post hyperoxic injury demonstrated reduced
lipid peroxidation and showed reduced leukocytes in BAL fluids. Analysis of tissue histology,
which is a direct measure of lung inflammation, revealed that AT-RvD1 treatment led to a visible
decrease in alveolar thickening, congestion, and alveolar immune cell infiltration in comparison
to mice treated with vehicle alone (Fig. 3.4A-E). Pathological severity scoring showed a small
improvement in tissue inflammation following 24 hr room air treatment; however, this
improvement was not significant. More importantly, administration of AT-RvD1 following
injury led to a significant improvement in pathological severity in comparison to the groups that
were exposed to hyperoxia alone and hyperoxia followed by saline treatments (Fig. 3.4F). To
further confirm the effects of AT-RvD1 treatment, lung edema and alveolar leak were examined
by the wet to dry ratio and BAL protein analysis, respectively (Fig. 3.5). AT-RvD1-treated mice
experienced a significant decrease in both lung wet-to-dry ratio and BAL protein levels
following hyperoxia. This reduction in lung edema by AT-RvD1 was further confirmed by a
decrease in dye extravasation into both the serum and the BAL fluid. (Fig. 3.6). Altogether, these
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results highlight AT-RvD1’s role in improved tissue histology, permeability reduction, and
prevention of further lung damage following injury.

AT-RvD1 Regulates Hyperoxia-Induced Inflammatory Mediator Production
The secretion of inflammatory mediators disrupts the immune-repressed alveolar state of
resident macrophages and epithelial cells. In vitro and in vivo reports from our laboratory
demonstrate that one of these mediators, Interleukin-1β (IL-1β), plays an important role in the
inflammatory phenotype seen in the lung following hyperoxic exposure (11, 14, 30). Therefore,
the influence of AT-RvD1 treatment on IL-1β secretion post-hyperoxic exposure was analyzed.
In comparison to mice treated with vehicle, AT-RvD1 treatment significantly decreased IL-1β
protein expression and secretion (Fig. 3.7A). Early cytokines released following injury, such as
IL-6 and MCP-1, show a similar decrease with AT-RvD1 treatment (Fig. 3.7B & 3.7C). To
further understand the mechanism of AT-RvD1 mediated reduction of hyperoxia-induced IL-1β
expression, the activity of transcriptional regulator NFκB was analyzed. Lung tissue analysis
reveals a decrease in NFκB activity with AT-RvD1 treatment compared to mice treated with
vehicle alone, as measured by the phosphorylation of the nuclear NFκB p65 subunit (Fig. 3.7D).
Mitogen activated protein kinases (MAPKs) are critical mediators for the activation of
transcription factors, such as NFκB, that lead to cytokine processing following inflammatory
stimuli. AT-RvD1 treatment resulted in an overall decrease in phosphorylation of MAPK p38
(Fig. 3.7E); however, no changes in the phosphorylation of p44/42 and SAPK/JNK were
detected (Fig. 3.8). These data demonstrate that AT-RvD1 treatment following hyperoxic
exposure results in enhanced resolution of proinflammatory cytokine secretion and the reduction
of proinflammatory signaling molecule activity
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AT-RvD1 Treatment Following Injury Results in Decreased Hyperoxia-Associated
Apoptotic Markers in Lung Tissue
Hyperoxia treatment leads to increased cellular apoptosis in lung tissue (9-11, 30).
Caspase-3 is a well-documented indicator of cellular apoptosis (53-55). Caspase-3 activity was
assessed in lung tissue sections and whole lung homogenates via IHC and Western blot,
respectively, to further assess cellular apoptosis. The results demonstrated a decreased presence
of active caspase-3 in lung sections and protein extracts prepared from mice given AT-RvD1
versus those given vehicle following hyperoxic exposure (Fig. 3.9 A-D). Proteins of the proapoptotic BCL-2 family (BH3-only proteins) regulate apoptosis through interaction and
inhibition of pro-survival molecules. Expression and activation of BH3-only proteins are
important hyperoxia-induced signaling events that lead to epithelial cell death in ALI (8, 13).
Phosphorylation of BH3-only protein BAD abolishes its pro-apoptotic activity. To confirm ATRvD1’s capability to reduce hyperoxia injury-induced apoptotic markers such as BAD,
phosphorylation of BAD was analyzed from each sample. AT-RvD1 treatment, in comparison to
vehicle control, resulted in increased phosphorylation of BAD in mice following hyperoxia
exposure (Fig. 3.9 E). No significant change in total BAD was observed between AT-RvD1 and
the vehicle-treated groups. BH3-only protein BIM also demonstrated reduced protein expression
in mice given AT-RvD1 following hyperoxic injury in comparison to vehicle control (Fig. 3.9
F). These results suggest that AT-RvD1 treatment results in decreased apoptotic activity through
suppression of BH3-only protein expression and signaling. These results suggest further
attenuation of hyperoxia-induced apoptotic signaling by AT-RvD1 treatment.
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Discussion
Hyperoxic therapy is a key component of supportive care for patients suffering from
reduced respiratory function (56). Prolonged exposure of high concentrations of hyperoxia can
lead to the generation of reactive oxygen species which can lead to hyperoxic acute lung injury
(HALI) which at times presents as acute respiratory distress syndrome(57). Injury resulting from
hyperoxic stress leads to decreased lung biomechanics, increased alveolar permeability, lung
edema, and inflammation (30, 58). Free radical generation may also result in increased apoptotic
signaling(59). While our laboratory as well as others have sought to dissect the molecular
determinants associated with hyperoxic acute lung injury (3, 60), the molecular determinants
involved in the restoration of innate tissue homeostasis and resolution of hyperoxic injury have
not been clearly defined. In this study, we hypothesized that the pro-resolution mediator Aspirin
Triggered-Resolvin D1 can enhance resolution of hyperoxic lung injury through decreased
oxidative stress, lung resistance, permeability, inflammation and apoptotic marker expression
(30, 61-63). Previous reports have demonstrated uniform animal death of mice exposed to 72-96
hours of 95% hyperoxia (6, 64), because of this we chose to investigate at the 48 hr time point
where moderate HALI pathology occurs and resolution after 24 hrs of injury can be investigated.
In studying resolution, the hyperoxic model has its advantages as natural resolution takes place
with mild scarring without fibrotic development (16, 17). Hyperoxia-induced reactive oxygen
species generation contributes to enhanced lipid peroxidation and subsequent cellular injury (42,
55, 65, 66). Our laboratory and others have shown that hyperoxia overexposure results in the
hyperactivation and ungoverned recruitment of proinflammatory leukocytes which include
neutrophils and monocytes (8, 11, 30). In the latter stages of injury, the production of
inflammatory mediators and reactive species by these cells contributes to a toxic alveolar
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environment and further damage of healthy tissue. Results from this study demonstrate that ATRvD1 treatment following injury shows reduced lipid peroxidation, a key indicator of oxidative
stress, in comparison to both hyperoxia and hyperoxia followed by vehicle treatment. For the
first time, we show that lipid peroxidation is reduced with AT-RvD1 treatment. It has been
previously discussed that diet rich in docosahexaenoic acid, precursor of AT-RvD1, curbs
oxidative stress and lipid peroxidation in rats following traumatic brain injury (67, 68). Our
results further affirm these findings and point to AT-RvD1 as a key DHA metabolite in the
reduction of oxidative stress following injury. DHA treatment has also been associated with
increased antioxidant properties (69), however the effects of AT-RvD1 on redox signaling has
not been studied. Our results reveal increased GSH and Nrf2 expression with AT-RvD1
treatment. GSH supplementation has been demonstrated previously to enhance resolution of
hyperoxic injury and is a major marker of oxidant antioxidant imbalance (33). Nrf2, a master
regulator of antioxidant gene expression, has also been demonstrated to be important in
resolution of hyperoxia induced acute lung injury through GSH regulation (33, 34, 40). Since
previous reports of AT-RvD1’s beneficial action on acute injury are not a result of oxidative
stress (27) and the hyperoxia model is based on injury as a result of oxidative stress, our finding
that antioxidants such as GSH and regulators such as Nrf2 are enhanced is of great significance
and represents a key next step of investigation as to how AT-RvD1 can combat oxidative stress.
More specifically, this paper provides a platform and basis to assess in the future whether
increased antioxidant machinery generated by AT-RvD1combats the antioxidant depletion and
subsequent redox imbalance caused by hyperoxia (38, 42, 45) and whether or not AT-RvD1 be
used as a therapeutic agent to increase antioxidant machinery and improve the effects of oxygen
therapy.
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Hyperoxic injury results in increased lung stiffening, inflammation and permeability (8,
48, 56, 58, 70). Whether or not AT-RvD1 could curb these hallmarks of hyperoxic lung injury
needed to be investigated. AT-RvD1 treatment following injury resulted in a significant decrease
in lung resistance. Lung static compliance was also improved with AT-RvD1 treatment in
comparison to hyperoxia alone; however, it was not significantly different than vehicle treatment
alone during the resolution recovery period (data not shown). These findings suggest that ATRvD1 can alleviate lung stiffening and improve respiratory mechanics following hyperoxic
injury. This is important as decreased respiratory function, in particular through increased airway
resistance, is associated with fibrotic development (71) Results of this study demonstrated that
treatment with AT-RvD1 following injury resulted in a much more significant reduction of
leukocytes and tissue inflammation in the 24 hr injury resolution phase than the vehicle control.
BAL fluid collection revealed decreased neutrophil counts in mice treated with AT-RvD1
following injury in comparison with hyperoxia and vehicle control. Reduced neutrophil
accumulation in BAL following injury may be a result of decreased expression and secretion of
neutrophil chemoattractants such as KC. Further, peroxidase enzyme myeloperoxidase (MPO)
was also reduced with AT-RvD1 treatment in comparison to vehicle treatment groups. Reduced
KC and MPO have been extensively associated with reduced neutrophilia and tissue
inflammation (72-79). Treatment with AT-RvD1 following hyperoxic injury also restored
normal leukocyte population as the macrophage population in the BAL was increased by 17% in
comparison to vehicle control, and the neutrophil population was reduced to 3% in comparison
to 20% for the vehicle control. These results point to the ability of AT-RvD1 to decrease
leukocyte inflammation and restore the leukocyte imbalance due to hyperoxic injury; however
whether this is attributed to decreased oxidant stress and an enhanced antioxidant profile was not
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thoroughly investigated. In future studies we aim to identify the link between the enhanced
antioxidant activity stimulated by AT-RvD1 and the reduced inflammatory phenotype shown
following AT-RvD1 treatment.
Leukocyte infiltration is a prime indicator of inflammation which is a key hallmark of
HALI and ungoverned regulation of inflammation results in downstream fibrotic development
(80). Hyperoxic injury and cell damage leads to the release of proinflammatory cytokines such as
IL-1β (11, 81, 82), which has been shown to be the most bioactive cytokine in lung injury
patients (83). This laboratory has demonstrated that decreased IL-1β secretion results in
improved lung pathology following hyperoxia challenge (11, 30). The results of this paper reveal
that AT-RvD1 versus control treatment results in decreased expression of pro-IL-1β.
Furthermore, IL-1β secretion is decreased following hyperoxia in mice given AT-RvD1 versus
vehicle treatment. IL-1β, as one of the early cytokines secreted by alveolar macrophages
contributes to hypercytokinemia following injury (83, 84). Thus it was hypothesized that with
AT-RvD1 treatment would also result in a decrease of other proinflammatory cytokines.
Analysis of proinflammatory cytokines, IL-6, KC, and MCP-1, in BAL revealed a similar
decrease in mice given AT-RvD1 following hyperoxia exposure in comparison to vehicle
treatment. While numerous reports from our laboratory have touched on the proteolytic
processing of pro-IL-1β that is needed for activity (11, 14, 30), interestingly we found decreased
expression of IL-1β in its pro-form which suggested that AT-RvD1 treatment resulted in
reduced transcriptional activity, leading to reduced IL-1β expression. Previous reports have
linked the AT-RvD1 receptor, formyl peptide receptor 2 (FPR2/ALX) with decreased activity of
proinflammatory transcription regulator, NF-κB (28). NF-κB and mitogen-activated protein
kinases (MAPKs) are important proinflammatory transcription regulators responsible for the
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activation of proinflammatory genes associated with the production of cytokines, adhesion
molecules, and epithelial cell junction destabilization (85-88). These downstream products of
NF-κB and MAPK activity contribute to the propagation of the proinflammatory cascade.
Investigation into AT-RvD1’s effect on NF-κB activity following hyperoxia exposure revealed a
significant decrease in phosphorylation of NF-κB following AT-RvD1 in comparison to vehicle
control treatment. Phosphorylation of NF-κB is a key signaling event involved in the
transcriptional activity of this molecule. Therefore, these results demonstrate that AT-RvD1
treatment significantly impairs NF-κB activation. Similar effects are seen in p38 MAPk
activation; however, the phosphorylation of the SAPK/JNK and p44/42 MAPks was not altered
with AT-RvD1 treatment. Data obtained from this study further demonstrates that AT-RvD1
versus control significantly resolves hyperoxia-induced inflammatory signaling and subsequent
cytokine secretion. The role of FPR2/ALX in this AT-RvD1 mediated attenuation of hyperoxia
induced inflammatory signaling still needs to be investigated in future studies.
The alveolar capillary-barrier plays an important homeostatic role in the regulation of
immune cell infiltration (1-3, 56). However, powerful inflammatory stimuli, such as hyperoxia,
cause deterioration and remodeling of this barrier, which leads to aberrant and overactive
inflammatory signaling (11, 56). Re-establishment of this barrier and decreased permeability are
key steps in HALI resolution. AT-RvD1 treatment following hyperoxia exposure demonstrates a
significant decrease in both the lung wet to dry ratio and alveolar protein content in comparison
to vehicle control. Further, AT-RvD1 treatment also demonstrates reduced epithelial and
vascular permeability. Altogether, these results suggest that treatment of following injury
reduces pulmonary edema and lung permeability. More importantly, these results suggest that
AT-RvD1 significantly enhances barrier integrity during the resolution phase of hyperoxic

86

injury. Because inflammatory cytokines contribute to hyperoxia-induced alveolar permeability
and barrier dysfunction, the ability of AT-RvD1 to suppress cytokine secretion may also
contribute to the enhanced barrier integrity seen in this study. Tissue histology following ATRvD1 administration was assessed since the build-up of edema fluid that ensues from the
compromised alveolar capillary barrier can lead to further activation of the alveolar epithelium,
endothelium, and macrophages (2). Pathological severity scoring from lung tissue sections
further illustrated the pro-resolution effects of AT-RvD1 versus the control as tissue sections
obtained from mice revealed improved tissue histology in areas of alveolar thickening, leukocyte
infiltration, and decreased alveolar congestion. Changes in alveolar hemorrhage were not
witnessed in these sections. Along with the improvement in permeability and decreased
pathological severity scoring, mice administered AT-RvD1 during the resolution phase
demonstrated less lung resistance and thus improved respiratory tract airflow. Taken together,
these results suggest that AT-RvD1 significantly improves recovery time from injury. Results
from this study demonstrate significant suppression of the ALI pathological severity. More
importantly, our results suggest that AT-RvD1 may be acting on multiple protective pathways,
which may point to the remarkable recovery seen in these mice treated with AT-RvD1.
Apoptotic cell death of alveolar epithelial cells is a previously described result of
hyperoxic insult (6). Cellular fragments, inactivated surfactant, and cellular contents from
apoptotic cells result in further secretion of noxious stimuli into the pulmonary milieu (56).
Previous reports from our laboratories have shown that BH3-only proteins play a role hyperoxiainduced apoptotic signaling (8, 13). BAD is a pro-apoptotic family member of the BH3-only
protein faction of the Bcl-2 family. Found primarily in the cytosol, BAD interacts with antiapoptotic proteins in order to prevent their mechanism of inhibition of apoptosis.
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Phosphorylation of BAD leads to inactivation and allows the pro-survival function of antiapoptotic members of the Bcl-2 family (apoptosis). Results from this study show that treatment
with AT-RvD1 versus the vehicle control significantly increased phosphorylation of BAD. More
importantly, these results suggest for the first time that AT-RvD1 may affect the apoptotic
signaling pathway through regulation of the proapoptotic BH3-only protein signaling cascade.
Expression of fellow pro-apoptotic protein BIM, showed a reduction in protein expression with
AT-RvD1 treatment following hyperoxic injury in comparison to vehicle controls. Caspase-3
activation was measured to confirm the resulting decreased apoptosis. IHC staining showed an
intense staining, localizing active caspase-3 expression mostly to the lung epithelial cells
(bronchiolar and some alveolar staining) in the vehicle treatment group; however, AT-RvD1
treatment following injury resulted in a significantly decreased expression in active-caspase-3
via two distinct methods. Strong staining in shown in the distal bronchiolar epithelial cells and to
a lesser extent, the alveolar epithelium, which is consistent with previous reports regarding
hyperoxia induced pro-apoptotic signaling (89, 90) These results further support AT-RvD1’s
capability to resolve hyperoxia-induced apoptotic signaling.
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Figures

Figure 3.1: AT-RvD1 treatment following hyperoxic lung injury demonstrates improved
lung mechanics and decreased oxidative stress. C57BL/6 mice were subjected to hyperoxia or
normoxia exposure for 48 hrs followed by treatment with AT-RvD1 (Structure shown in panel
A,) or saline vehicle for 24 hrs administered IV (Treatment outline shown in panel B). (C) In a
separate experiment, lungs were harvested from each mouse and lipid peroxidation was
measured via the thiobarbituric acid reactive substances assay. Prior to euthanasia, (D) Lung
resistance was measured following each treatment using the flexiVent respiratory metrics
apparatus (see methods). A one-way ANOVA, with a Tukey post-hoc test, was used to determine
the results where a p-value of p < 0.05 was deemed statistically significant (N = 6 for each
group).
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Figure 3.2: AT-RvD1 treatment following hyperoxic injury reduces cells in BAL fluid and
rescues leukocyte imbalance. C57BL/6 mice were subjected to normoxia or hyperoxia exposure
for 48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in
normoxia. An equal mixture of BAL fluid was collected and cytospun unto microscope slides for
leukocyte analysis. Cytospin smears were stained via Diffquick stain. Total (A) and differential
cell (B-C) count was performed. Analysis of the BAL macrophage and neutrophil percentage
was also calculated (D). A one-way ANOVA, with a Tukey post-hoc test, was used to determine
the results where a p-value of p < .05 was deemed statistically significant (n = 10 in each group).
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Figure 3.3: AT-RvD1 treatment following hyperoxic injury enhanced clearance of cellular
debris and cell infiltrate in BAL fluid. C57BL/6 mice were subjected to normoxia or hyperoxia
exposure for 48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in
normoxia (n = 6 for each group). An equal mixture of BAL fluid was collected and cytospun
unto microscope slides for leukocyte analysis (A-E). Representative images for each group are
shown (A-E). Original magnification: 100X. Neutrophils in BAL fluid are highlighted by black
arrows. Murine neutrophilic chemokine KC from BAL fluid (F) as well as myeloperoxidase from
lung homogenates (G) was also measured. A one-way ANOVA was used to determine the results
where a p-value of p < 0.05 was deemed statistically significant (n = 10 in each group).
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Figure 3.4: AT-RvD1 regulates hyperoxia enhances resolution of hyperoxia-induced tissue
inflammation. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for 48 hrs
followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in normoxia (n = 6 for
each group) administered IV. Lung sections were obtained and stained with H&E to analyze lung
histology (A-E). Original magnification: 40X. Representative images for each group are shown.
(F) Four independent parameters (alveolar congestion, hemorrhage, leukocyte infiltration, and
alveolar wall thickness) were scored and used to determine the acute lung injury severity score.
These are the cumulative results of three independent experiments (n = 10 in each group). A oneway ANOVA was used to determine the results where a p-value of p < .05 was deemed
statistically significant.
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Figure 3.5: AT-RvD1 treatment following hyperoxia demonstrates reduced pulmonary
edema and permeability. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for
48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n = 6 for each
group) administered IV. (A-B) Following AT-RvD1 or vehicle treatment, lungs tissue was
harvested and the weight of the “wet” lungs was measured. Lungs were placed in an oven at
70°C and measured periodically until the measurement was constant (“dry weight”). The wet/dry
ratio was measured for each group. (C-D) In a separate subset of animals (n = 6 for each group),
BAL fluid was collected. Following AT-RvD1 or vehicle treatment and total protein in BAL
fluid for each group was measured via BCA assay. A one-way ANOVA was used to determine
the results where a p-value of p < .05 was deemed statistically significant.
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Figure 3.6: AT-RvD1 blunts hyperoxia-induced alveolar permeability and pulmonary
edema. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for 48 hrs followed by
treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n = 6 for each group)
administered IV. (A) Endothelial barrier integrity was determined via introduction of Evans Blue
dye administered intravenously 30 minutes prior to the end of each treatment. Following
euthanasia, quantification of Evans blue dye in the BALF was used to examine endothelial
barrier integrity. In a separate experiment, (B) epithelial barrier integrity was assessed by
analyzing the serum-to-BALF ratio of extravasated 3000MW FITC dextran, administered
intratracheally 20 minutes prior to end of each treatment. A one-way ANOVA was used to
determine the results where a p-value of p < .05 was deemed statistically significant.
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Figure 3.7: AT-RvD1 treatment following injury attenuates hyperoxia-induced cytokine
expression and secretion. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for
48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in normoxia (n
= 6 per group). Following AT-RvD1 or vehicle treatment, BAL Fluid was collected from mice in
each group. Enzyme linked immunosorbant assays were performed using BAL fluid to assess
cytokine secretion of (A) IL-1β, (B) IL-6, and (C) MCP-1. In a separate experiment (n = 6 per
group), total protein was extracted and used for western blot analysis of phosphorylation of (D)
NFκB P65 subunit (in the nuclear fraction) and (E) p38 MAP Kinase. T = total, p =
phosphorylated form of assayed proteins. Densitometry of each phosphorylated protein shown
below the blot and is representative of three separate experiments. Representative blots of each
group for each protein are shown. A one-way ANOVA (for each ELISA) or Student t-test (blot
densitometry) was used to determine the results where a p-value of p < .05 was deemed
statistically significant.
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Figure 3.8: AT-RvD1 Treatment following injury does not result in enhanced P44/42 and
SAPK/JNK MAP Kinase activity. C57BL/6 mice were subjected to normoxia or hyperoxia
exposure for 48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n
= 6 for each group) administered IV. Following AT-RvD1 or vehicle treatment, lung tissue was
collected from mice in each group. Total protein was extracted from harvested tissue and used to
run for western blot analysis of the phosphorylation of (A) P44/42 (B) SAPK/JNK MAP kinases.
T=total, p=phosphorylated form of assayed proteins. Densitometry of each phosphorylated
protein shown below the blot and is representative of three separate experiments. Representative
blots of each group for each protein are shown. Student test was used to analyze statistical
significance, where a p-value of p < .05 was considered statistically significant.
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Figure 3.9: AT-RvD1 decreases hyperoxia-induced pro-apoptotic protein expression.
C57BL/6 mice subjected to hyperoxia treatment for 48 hrs followed by treatment with AT-RvD1
(100 ng) or saline vehicle for 24 hrs (n = 4 for each group) administered IV. Following ATRvD1 or vehicle treatment, Lung tissues from each group were fixed in formalin and embedded
in paraffin blocks. (A-C) IHC was performed on lung tissue sections to examine the expression
of active caspase-3. Original magnification: 100X; insets, 200X. To further measure apoptotic
markers, lung tissue homogenates were examined for the presence of (C) active-caspase-3, (D)
phosphorylated and total BAD, and (E) BIM via Western blot. The densitometry of each protein
is shown to right of its respective blot. Student test was used to analyze statistical significance,
where a p-value of p < .05 was considered statistically significant.
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Figure 3.10 AT-RvD1 treatment following injury leads to enhanced glutathione production
and Nrf2 expression. C57BL/6 mice subjected to hyperoxia treatment for 48 hrs followed by
treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n = 4 for each group)
administered IV. Following AT-RvD1 or vehicle treatment, lung tissue was collected from mice
and in each group and divided into sections for assay screening. (A) Glutathione (GSH) detection
assay was used to measure GSH levels. (B) After obtaining mRNA from lung tissue, qPCR
analysis was perfumed to identify Nrf2 expression. Both assays are shown relative to room air
controls. A one-way ANOVA (for each ELISA) or Student t-test (blot densitometry) was used to
determine the results where a p-value of p < .05 was deemed statistically significant.
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Chapter 4: Summary and Conclusions

Summary
Acute lung injury is a devastating respiratory syndrome featuring a progressive
inflammatory cascade. Attempts at treatment of this deadly disease have failed and mechanical
ventilation at high fraction of inspired oxygen is currently the only useful form of supportive
care. Prolonged exposure to high concentrations of oxygen results in the development of
hyperoxia induced acute lung injury. Reactive oxygen species generated during this injury
initiate a vicious and recurrent cycle of injury and death [1]. Prolonged exposure to hyperoxia
dysregulates endogenous repair and resolution machinery, however sublethal and self-limiting
time points of hyperoxia exposure has enabled us to examine key factors involved in injury
resolution.
Poly unsaturated fatty acids already play a key role in the patient ICU setting as
parenteral feeding with omega-3 fatty acids results in better patient outcomes [2,3]. However
their role in the resolution of injury is not properly understood and has led to significant
investigation in recent reports. By products of omega-3 fatty acids EPA and DHA, termed
resolvins, have gained considerable acclaim for their ability to reduce proinflammatory cytokine
secretion while promoting macrophage uptake of apoptotic neutrophils in various acute models
of injury [4]. One of these products, AT-RvD1 was recently reported to be particularly important
in the resolution of injury by acid inspiration, however as reported by eickmeier, the oxidative
stress was relatively low and did not contribute to the examination of injury resolution by
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resolvins [5]. Since our previous reports have detailed the effects of oxidant injury on alveolar
permeability, inflammation and apoptosis [6-9], we chose to examine AT-RvD1 as a potential
candidate molecule to alleviate the hyperoxia mediated ALI hallmarks. In vitro investigation
revealed that AT-RvD1 significantly decreased oxidant induced macrophage secretion of
proinflammatory mediator IL-1β. AT-RvD1’s was able to show significant attenuation of IL-1β
at low nanomolar levels and was more potent than its RvD1 epimer as well as RvD2 in
preliminary studies. More importantly we saw that AT-RvD1 treatment resulted in reduced
macrophage related alveolar activation via reduction of IL-1β signaling. While a weakness of
this study was that we did not use of IL-1β receptor activators in order to see if we can rescue the
macrophage induced secretion of cytokines from alveolar epithelial cells, the use of an IL-1
receptor antagonist, enables us to highlight that IL-1β related decrease does play a role in ATRvD1’s beneficial actions on both the macrophage and the alveolar epithelium. Further, the
reports of IL-1β being the most bioactive cytokine in the lungs of acute lung injury patients
serves to confirm our thoughts about the importance of this molecule [10].
In an effort to examine if direct IL-1β mediated stimulation and activation could be
affected by AT-RvD1 treatment, alveolar epithelial cells were treated with recombinant IL-1β in
the presence or absence AT-RvD1. Results demonstrated not only a reduction in signaling but
also reduced function. Not only was there reduced cytokine expression and adhesion with ATRvD1 treatment, but epithelial to leukocyte adhesion was also hampered as a result of this
effects. The ability of AT-RvD1 to hamper leukocyte adhesion is reported for the first time and
is quite significant as leukocyte influx into the alveolar space is consistent with injury
progression and outcome [1,11,12].
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Resolvins are well documented molecules involved in activation of proresolution
machinery. Oxygen is also an important and unavoidable form of supportive care, however the
effects of prolonged oxygen exposure are significant. Therefore, we wanted to examine how
resolvins, specifically AT-RvD1 can enhance the resolution of lung injury as a result of oxidative
stress. Resolvin in the oxygen toxicity setting had not been studied previously. We exposed mice
to a hyperoxic atmosphere (≥ 95%) for 48hrs. At this time point under hyperoxic conditions,
mice develop a moderate form of lung injury that heals with little tissue scarring [13]. Following
this exposure mice we left to resolve in normoxic conditions or given AT-RvD1 intravenously.
While mice allowed to resolve from injury in a 24hr period showed moderate signs of injury
resolution, mice given AT-RvD1 showed significant improvement from injury. Oxidative stress
was reduced in this mice and respiratory biomechanics such as lung resistance was significantly
improved. Hallmarks of ALI showed significant resolution in mice treated with AT-RvD1 as
opposed to those mice left to recover in normoxic conditions without AT-RvD1 treatment.
Tissue inflammation, alveolar permeability and edema, epithelial apoptosis, were all reduced in
AT-RvD1 treated mice. Proinflammatory cytokine signaling was reduced in AT-RvD1 treated
mice in comparison to vehicle controls. BAL fluid cytosmears show reduced leukocyte content
and cell debris in AT-RvD1 treated mice in comparison to vehicle controls. Whether or not this
is due to reduced adherence and uptake of leukocytes as shown in in vitro studies or it is a result
of enhanced macrophage mediated neutrophil clearance needs to be investigated and represents a
key future study. While resolvins demonstrate potential proresolution effects in HALI, these
studies reveal an entirely new area of beneficial effects for resolvins. For the first time, these data
demonstrate that AT-RvD1 enhances resolution of injury associated with oxygen toxicity. They
also demonstrate that treatment with the pro-resolution agonist, AT-RvD1, both reverses
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hyperoxia mediated proinflammatory and proapoptotic signaling and aids in the homestatic
return to normal lung physiology (shown in figure 4.1). More importantly our results highlight an
alteration in antioxidant production and transcription factor expression coupled with decrease
oxidative stress. These results provide evidence for a novel role of AT-RvD1 in regulating
hyperoxia-induced lung inflammation and acute injury. Thus far our studies as well as others
have demonstrated a one hit system of acute injury, however patients also suffer from a myriad
of complications that are both sterile and pathogen induced. It’s of interest to us to investigate
the effects of AT-RvD1 in a two hit system that combined sepsis as well as sterile injury, such as
hyperoxia and LPS. It is also of interest to look at the mechanistic insights of resolvin mediated
proresolution of injury. Formyl peptide receptor 2 (FPR2/ALX) is a well-documented highaffinity receptor for both RvD1 and AT-RvD1. FPR2/ALX activation conveys significant antiinflammatory properties as reported previously [4,14-16]. Preliminary investigation of
FPR2/ALXs role in the beneficial effects of AT-RvD1 were promising (Figure 4.3) A549 cells
exposed to hyperoxia and IL-1β demonstrate enhanced surface expression of ALX/FPR2. Similar
to recent reports where acid induced injury lead to an increase in ALX/FPR2 expression [5].
ALX/FPR2 expression may be expressed in response to inflammatory signals in an anticipatory
fashion to serve as a homeostatic mechanisms when lipid mediators are produced. In A549 cells
treated with IL-1β in the presence or absence of AT-RvD1, AT-RvD1 reduced IL-1β mediated
NF-κB. This effect was significantly diminished when ALX/FPR2 inhibitor N-t-Boc-Phe-LeuPhe-Leu-Ph (BOC-2). These studies suggest that further investigation of role of ALX/FPR2 in
AT-RvD1’s beneficial effects in an oxidant toxicity setting is warranted.
From a clinical perspective, activating RvD1 producing pathways by a pharmacological
approach may serve to disrupt the inflammatory cascade and ultimately may provide a novel
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therapeutic strategy for the protection of lung tissue from cellular injury during acute or chronic
illness associated with ALI syndromes. Further understanding of the mechanisms of AT-RvD1
mediated HALI resolution may lead to the development of clinical interventions for the
protection of patients requiring supplemental oxygen
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Figures

Figure 4.1: Aspirin triggered Resolvin D1 attenuates progressive HALI hallmarks that
impede injury resolution. In a normal lung, hyperoxic exposure leads to macrophage secretion
of IL-1b which triggers the epithelial cell response. Disruption of the epithelial barrier occurs
and allows an influx a neutrophils along with increased macrophage activation and secretion of
proinflammatory cytokines. Epithelial and inflammatory cells undergo apoptosis, leading to an
overall accumulation of dead cell debris, ROS, cytotoxic enzymes, and a continuation of the
inflammatory response. Treatment with AT-RvD1 results in decreased macrophage secretion of
proinflammatory cytokines, such as IL-1b, and reduced activation of alveolar epithelial cells.
Thus, lung permeability, neutrophil infiltration, macrophage activation and release of cytokines
are significantly attenuated, enhancing injury resolution and clearance of leukocytes.
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Figure 4.2: Future Directions. ALX/FPR2 is a well-documented receptor for both RvD1 and
AT-RvD1 with higher binding affinity than formyl peptide substrate. Preliminary studies reveal
an increase in alveolar epithelial surface expression of this receptor following 24hr hyperoxia
exposure. Blunting the receptor with chemical inhibitor boc-1 results in enhanced IL-1β
mediated signaling of proinflammatory mediator NF-κB.
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Clinical Significance

Figure 4.3: Clinical Significance. The development of pharmacological components that
enhance the biosynthesis of resolvins could lead to a significant improvement in patient care and
effectiveness of oxygen therapy due to decreased oxidant mediated injury.
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